| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Imunon, Inc.$2.02
+0.01 (+0.5%)
D 26Pipeline Score Overvalued Biotech · Clinical
Market Cap
9.24 M
EPS
-5.17
P/E Ratio
-
Value Trade
72.75 K
SEC Financials
Q1 2026Dilution Risk
R&D Expenses
2.34 M
Operating CF
-3.99 M
Total Assets
8.02 M
Total Liabilities
4.66 M
Equity
3.36 M
D/E Ratio
12,345
-11.65 %
Week
-27.39 %
1 Month
-33.03 %
3 Month
-40.86 %
6 Month
-99.03 %
5 Year
-100 %
All Time
Cash Data
Cash Position
4.79 M
Monthly Burn
1.33 M
Runway
1.9 mo
Burn Trend
StableSEC Filing
May 12, 2026
Overview
Volume
13.50 K
52 Week Range
2.08 - 41.22
% held by Insiders
8.6 %
% held by Institutions
11.98 %
Enterprise Value
5.36 M
Total Shares
3.92 M
Short %
2.19 %
Float Shares
2.33 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Imunon, Inc.
691Total events
4Upcoming
135Tier-1 (high impact)
2011 – 2029Coverage
Upcoming catalysts 4
TBD
T2Timing Guidance
Potential early data readout from HRD-positive subgroup (250 patients) expected
Event history 687
Jun 23, 2026
▲DSMB ReviewIMNN-001Trial
iDMC recommends continuation of OVATION 3 without modification
newly diagnosed advanced ovarian cancersource ↗
Jun 23, 2026
◆Enrollment UpdateIMNN-001Trial
27 patients enrolled to date
newly diagnosed advanced ovarian cancersource ↗
Jun 4, 2026
▼Equity OfferingCorporate
Up to $10 million cash financing including preferred stock and promissory notes
Jun 4, 2026
▲Full ResultsIMNN-001Clinical Data
Updated Phase 2 final data showing 14.7-month median OS improvement
newly diagnosed advanced ovarian cancersource ↗
Jun 4, 2026
◆Enrollment UpdateIMNN-001Trial
Phase 3 OVATION 3 study currently enrolling
newly diagnosed advanced ovarian cancersource ↗
May 12, 2026
◆Quarterly UpdateCorporate
First Quarter 2026 Financial Results and Business Update Conference Call
May 12, 2026
▲Enrollment UpdateIMNN-001Trial
Enrollment in OVATION 3 continues ahead of plan
newly diagnosed advanced ovarian cancersource ↗
May 12, 2026
▲FDA Feedback ReceivedIMNN-001FDA Meeting
FDA reviewed and aligned with Phase 3 protocol, confirms path to BLA filing
newly diagnosed advanced ovarian cancersource ↗
Mar 31, 2026
Mar 25, 2026
▲Full ResultsIMNN-001Clinical Data
Final data analysis from OVATION 2 shows median OS improvement of 14.7 months
newly diagnosed advanced ovarian cancersource ↗
Mar 25, 2026
▲Enrollment UpdateIMNN-001Trial
Enrollment in Phase 3 OVATION 3 trial remains ahead of plan
newly diagnosed advanced ovarian cancersource ↗
Drug Pipeline Intelligence
D26
Pipeline Score $2M
Pipeline ValueOvervalued
Valuation Signal5
Drugs Scored0.3x
rNPV / MCap Top 27%
Micro Cap (rank 666 of 911)
Percentile RankImunon, Inc. faces pipeline headwinds (26/100), with $658M risk-adjusted pipeline value, led by Olaparib in Epithelial Ovarian Cancer (Phase 3), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Olaparib Small molecule | Epithelial Ovarian Cancer | Phase 3 | NCT06915025 | 42% | $276M | RECRUITING | 500 | FAST | C (50) | Oct 31, 2032 | MODERATE_RISK | LOW Jul 6, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
IMNN-001 | advanced ovarian cancer | Phase 3 | 2026-06-23 | 27 patients enrolled to date | IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification Read More | |
IMNN-001 | advanced ovarian cancer | Phase 3 | 2026-06-23 | 27 patients enrolled to date | IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification Read More | |
IMNN-001 | advanced ovarian cancer | Phase 3 | 2026-06-23 | 27 patients enrolled to date | IMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in IMNN
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
IMNN Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
IMNNIMUNON Announces Data Monitoring Committee Recommends Continuation of Phase 3 OVATION 3 Study Without Modification
IMUNON, Inc. announced that its Phase 3 OVATION 3 study will continue without modifications, as recommended by the independent Data Monitoring Committee. The trial evaluates IMNN-001 in combination with standard chemotherapy for advanced ovarian cancer. Positive Phase 2 results indicated significant overall survival improvements, and the trial is on track to enroll 80 participants by Q1 2027.
Read more →IMNNIMUNON to Present at the Life Sciences Investor Forum on June 25th
IMUNON, Inc. will present at the Life Sciences Investor Forum on June 25, 2026. Dr. Stacy Lindborg, CEO, will discuss the company's Phase 3 DNA-mediated immunotherapy and its ongoing clinical programs. Investors can participate in real-time Q&A during the event, with an archived version available later. IMUNON focuses on innovative treatments for various diseases.
Read more →IMNNIMUNON Announces Up to $10 Million Cash Financing
IMUNON announced a financing deal worth up to $10 million to support its Phase 3 OVATION 3 study of IMNN-001 for advanced ovarian cancer. The financing involves preferred stock and secured promissory notes, designed to minimize dilution for shareholders. Positive Phase 2 clinical data indicating improved overall survival has bolstered confidence in the investigational therapy IMNN-001. The funds will be utilized for continued patient enrollment in the pivotal trial, which aims to evaluate the efficiency of IMNN-001 in combination with standard chemotherapy treatments.
Read more →IMNNIMUNON Announces Up to $10 Million Cash Financing Includes up-front issuance of preferred stock for $2.5 million and secured promissory notes for $7.72 million Uniquely structured, flexible financing supports IMUNON's Hi
IMUNON, Inc. announced a $10 million cash financing aimed at supporting its Phase 3 OVATION 3 clinical trial for IMNN-001 in advanced ovarian cancer. The financing includes issuance of preferred stock and secured promissory notes, with proceeds expected to enhance the company’s capital position. Updated clinical data from an earlier Phase 2 study has indicated improved survival outcomes for patients treated with IMNN-001 in combination with standard chemotherapy. This financing is seen as a strategic move to bolster shareholder value while progressing in clinical trials.
Read more →IMNNIMUNON Reports First Quarter 2026 Financial Results and Provides Business Update IMNN-001 is the First and Only frontline treatment candidate to demonstrate the potential for a clinically meaningful overall survival bene
IMUNON, Inc. has reported its financial results for Q1 2026 alongside a business update on its lead candidate IMNN-001 for advanced ovarian cancer. The drug has shown promising overall survival benefits in the Phase 2 OVATION 2 study, with recent data indicating a median increase of 14.7 months compared to standard chemotherapy. The ongoing Phase 3 OVATION 3 trial is expected to conclude by Q1 2029, and IMUNON is aligned for a potential BLA filing based on this data. However, the company also reported a net loss of $4.3 million for the quarter, amid rising operational costs.
Read more →IMNNIMUNON to Hold First Quarter 2026 Financial Results and Business Update Conference Call on Tuesday, May 12, 2026
IMUNON, Inc. will hold a conference call on May 12, 2026, to discuss its Q1 financial results and provide updates on its clinical development program for IMNN-001, a DNA-based immunotherapy for advanced ovarian cancer. The company is currently conducting a Phase 3 trial for this candidate, which aims to enhance cancer-fighting responses in patients.
Read more →IMNNIMUNON Reports 2025 Financial Results and Provides Business Update Highlighting Significant Progress with Pivotal Phase 3 Study IMNN-001 is the first frontline immunotherapy to demonstrate the potential for a clinically
IMUNON, Inc. has reported its 2025 financial results alongside a business update on the progress of its lead therapy, IMNN-001, in advanced ovarian cancer. The company highlighted significant advancements in the Phase 3 OVATION 3 study, noting that IMNN-001 is the first frontline immunotherapy showing potential for a clinically meaningful survival benefit. Results from the Phase 2 OVATION 2 study indicate an improvement in median overall survival of over 14 months for patients treated with IMNN-001. The therapy’s promising safety profile and strong data support its role in transforming treatment options for women with advanced ovarian cancer.
Read more →IMNN▼ -5.4%on this news
IMUNON Reports Updated Phase 2 Data Showing Continued Improvement in Median Overall Survival with IMNN-001 in Women with Newly Diagnosed Advanced Ovarian Cancer
IMUNON has reported updated Phase 2 data from the OVATION 2 trial, showing a median overall survival increase from 11.1 months to 14.7 months for women treated with IMNN-001. Additionally, patients receiving IMNN-001 alongside standard chemotherapy and PARP inhibitors experienced a median overall survival of 24.2 months. Enrollment for the Phase 3 trial is progressing ahead of schedule, reflecting strong interest in the treatment.
Read more →IMNNIMUNON to Hold 2025 Financial Results and Business Update Conference Call on Tuesday, March 31, 2026
IMUNON, Inc. will hold a conference call on March 31, 2026, to discuss its financial results for 2025 and provide updates on its clinical development program, particularly focusing on its lead candidate, IMNN-001. This DNA-based immunotherapy is in Phase 3 trials for advanced ovarian cancer. The call will be accessible via phone and webcast.
Read more →IMNNIMUNON SHARPENS FOCUS ON ITS PROMISING PIVOTAL PHASE 3 OVARIAN CANCER STUDY
IMUNON, Inc. is advancing its pivotal Phase 3 OVATION 3 clinical trial for advanced ovarian cancer. The company has restructured to eliminate non-essential expenses and is ahead of enrollment projections. CEO Stacy Lindborg emphasized the importance of resource efficiency and the promising results from previous studies. The retirement of Dr. Khursheed Anwer marks a significant transition for the company.
Read more →IMNNIMUNON Announces Pricing of $7.0 Million Registered Direct Offering Priced At-The-Market Under NASDAQ Rules
IMUNON, Inc. has announced a registered direct offering of $7.0 million priced at-the-market under NASDAQ rules. The offering involves the sale of approximately 1.94 million shares of common stock and warrants to purchase additional shares. The transaction is expected to close by December 31, 2025, subject to customary conditions. Maxim Group LLC is the lead placement agent for this offering.
Read more →IMNN▲ +20.6%on this news· ran to +31% by day 3shared move
IMUNON 2025, A TRANSFORMATIVE YEAR OF SIGNIFICANT CLINICAL ADVANCES, LOOKING AHEAD TO 2026
IMUNON, Inc. has made significant strides in 2025, particularly with the Phase 3 OVATION 3 Study of IMNN-001 for ovarian cancer. The study shows promising results, including extended overall survival rates. Additionally, new data from the MRD study supports the efficacy of IMNN-001. The company is well-positioned for continued success in 2026 with key milestones ahead.
Read more →IMNN▲ +5.3%on this news
IMUNON Reports Third Quarter 2025 Financial Results and Provides Business Update
IMUNON, Inc. reported its Q3 2025 financial results, highlighting advancements in the Phase 3 OVATION 3 Study for its lead candidate IMNN-001, aimed at treating advanced ovarian cancer. The company showcased positive survival data from the Phase 2 OVATION 2 Study and noted growing interest from the medical community. Despite a net loss of $3.4 million, IMUNON is strategically managing its resources to fund ongoing trials.
Read more →IMNNIMUNON Public Webcast Highlights Resilience and Innovation in Pursuit of the First Approved Immunotherapy for Ovarian Cancer
IMUNON, Inc. hosted a public webcast showcasing insights from cancer experts regarding its DNA-mediated immunotherapy, IMNN-001, which is in Phase 3 development for advanced ovarian cancer. The event highlighted promising clinical data and the company's innovative approach to treatment. IMUNON continues to advance its therapies while acknowledging the inherent risks in clinical research.
Read more →IMNN▼ -6.2%on this newsshared move
IMUNON R&D Day Showcases Clinical Progress of Its Novel Immunotherapy, Phase 3 Trial and Significant Potential for Women with Ovarian Cancer
IMUNON showcased its clinical progress on IMNN-001, a novel immunotherapy for ovarian cancer, during its R&D Day. The company highlighted positive results from the Phase 2 OVATION 2 Study, indicating a significant improvement in overall survival. The ongoing Phase 3 OVATION 3 trial aims to further validate these findings, with strong statistical support for its design.
Read more →IMNNIMUNON R&D Day: Opportunity to Hear Clinical Trial Investigators Discuss Significant Potential of IMNN-001 to Redefine Ovarian Cancer Treatment
IMUNON, Inc. will host an R&D Day on November 10, 2025, in New York City to discuss its DNA-mediated immunotherapy, IMNN-001, for advanced ovarian cancer. The event will feature principal investigators from the Phase 3 OVATION 3 trial, highlighting the urgent need for new treatment options. CEO Stacy R. Lindborg emphasized the potential impact of IMNN-001 on the future of ovarian cancer therapy.
Read more →IMNNIMUNON to Hold Third Quarter 2025 Financial Results and Business Update Conference Call on Thursday, November 13, 2025
IMUNON, Inc. will host a conference call on November 13, 2025, to discuss its third quarter financial results and provide updates on its clinical development program, particularly focusing on its lead candidate, IMNN-001. This DNA-based immunotherapy is currently in Phase 3 trials for advanced ovarian cancer. The call will be accessible via phone and webcast.
Read more →IMNN▼ -12.2%on this newsshared move
IMUNON Announces Webcast of In-Person R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
IMUNON, Inc. will host an R&D Day on November 10, 2025, in New York City to update investors on its Phase 3 OVATION 3 Study for the treatment of advanced ovarian cancer. The event will include presentations from key thought leaders and investigators, showcasing new data on the company's lead product, IMNN-001. Attendees can participate in-person or virtually.
Read more →IMNNIMUNON to Present Phase 3 OVATION 3 Study of IMNN-001 in Advanced Ovarian Cancer at IGCS 2025 Annual Global Meeting
IMUNON, Inc. announced its participation in the IGCS 2025 Annual Global Meeting to present the Phase 3 OVATION 3 study of IMNN-001, a DNA-mediated immunotherapy for advanced ovarian cancer. The therapy has shown effective responses in earlier trials, and the company is expanding clinical sites to accelerate patient enrollment. The study aims to validate the therapy's potential in improving overall survival rates.
Read more →IMNNIMUNON to Present New Translational Data from Phase 2 OVATION 2 Study of IMNN-001 at SITC 40th Annual Meeting
IMUNON, Inc. announced that new translational data from its Phase 2 OVATION 2 trial of IMNN-001 will be presented at the SITC 40th Annual Meeting. IMNN-001, a DNA-mediated immunotherapy, has demonstrated efficacy in treating advanced ovarian cancer. The company is also advancing its OVATION 3 pivotal Phase 3 trial, which aims to further validate the therapy's effectiveness.
Read more →IMNNIMUNON Hosts R&D Day Highlighting Progress on OVATION 3 Study in Pursuit of First Frontline Immunotherapy for Advanced Ovarian Cancer
IMUNON, Inc. will host an R&D Day on November 10, 2025, in New York City to discuss its pivotal Phase 3 OVATION 3 Study of the DNA-mediated immunotherapy IMNN-001. The event will feature presentations from leading experts in ovarian cancer and provide updates on the study's progress. Attendees will have opportunities for live Q&A and networking.
Read more →IMNNIMUNON Invited to Present PlaCCine® DNA Technology Proof-of-Concept Data in Platform Presentations at Leading Vaccine Conferences
IMUNON, Inc. announced that it will present data on its PlaCCine technology at two upcoming vaccine conferences. The presentations will highlight the investigational DNA plasmid vaccine IMNN-101, which has shown promising results in a Phase 1 trial. The company aims to secure partnerships to further develop its innovative vaccine platform.
Read more →IMNNIMUNON to Present Phase 3 Ovarian Cancer Study of IMNN-001 at ESMO Congress
IMUNON, Inc. announced that its Phase 3 OVATION 3 trial for IMNN-001, aimed at advanced ovarian cancer treatment, will be presented at the ESMO Congress 2025. IMNN-001, utilizing the TheraPlas® technology platform, is designed to enhance anti-cancer immunity through localized delivery of interleukin-12. The trial has commenced with patient enrollment at several sites, and previous studies have shown significant improvements in survival rates compared to standard treatments. The findings underscore the therapeutic potential of IMNN-001 in this critical area of oncology.
Read more →IMNNIMUNON Presents IMNN-001 Phase 2 Translational Data in Advanced Ovarian Cancer Demonstrating 13-Month OS Extension via Tumor Micro-Environment Shift
IMUNON, Inc. has presented promising Phase 2 data for its investigational immunotherapy IMNN-001 at the AACR conference, highlighting a substantial 13-month extension in overall survival for patients with advanced ovarian cancer. The OVATION 2 study revealed favorable changes in the tumor microenvironment, supporting the efficacy of IMNN-001 combined with standard chemotherapy. The company is advancing its pivotal Phase 3 OVATION 3 trial with active site expansion to accelerate patient recruitment following positive Phase 2 results.
Read more →IMNNIMUNON to Present New Translational Data of IMNN-001 Supporting Phase 3 Trial of Immunotherapy for Ovarian Cancer at AACR Special Conference in Cancer Research
IMUNON, Inc. announced that new data from its Phase 2 OVATION 2 Study of IMNN-001 will be presented at the AACR Special Conference in Denver. IMNN-001, a DNA-mediated immunotherapy targeting advanced ovarian cancer, has demonstrated promising capabilities in improving overall and progression-free survival rates compared to standard care. The ongoing Phase 3 OVATION 3 trial is expected to further evaluate this treatment’s effectiveness. The company continues to pursue its innovative non-viral DNA technology aimed at cancer treatment.
Read more →IMNNIMUNON to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
IMUNON, Inc. (NASDAQ: IMNN) announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference in New York on September 8-10, 2025. The company will have a pre-recorded presentation available on demand starting September 5, 2025. IMUNON focuses on developing DNA-mediated immunotherapies and has achieved significant milestones in clinical trials, including recent work on its lead program for advanced ovarian cancer and a COVID-19 booster vaccine. The company aims to advance its innovative treatment modalities to address challenging medical conditions.
Read more →IMNNIMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement LAWRENCEVILLE, N.J.
IMUNON, Inc. has announced that it has regained compliance with the Nasdaq's minimum bid price listing requirement, ensuring uninterrupted trading on the exchange. This news follows the company's recent issuance of a 15% stock dividend to enhance shareholder value and reflects ongoing confidence in its clinical pipeline, particularly its lead immunotherapy, IMNN-001, which is currently undergoing a Phase 3 trial. The company continues to advance its innovative TheraPlas technology platform as it works to develop treatments for challenging diseases, including advanced ovarian cancer.
Read more →IMNNIMUNON Recaps Highlights from 2025 Second Quarter Financial Results Conference Call
IMUNON, Inc. reported promising financial results and business updates during its second quarter 2025 conference call. The company highlighted progress in its Phase 3 OVATION 3 trial for IMNN-001, a novel immunotherapy for newly diagnosed advanced ovarian cancer, and introduced a 15% stock dividend for shareholders. Their operational focus includes cash conservation measures and a strong supply chain for manufacturing. The favorable reception of OVATION 2 study data has energized engagement from medical professionals for future trials.
Read more →IMNNIMUNON Reports Second Quarter 2025 Financial Results and Provides Business Update Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewardi
IMUNON, Inc. (IMNN) announced its Q2 2025 financial results, detailing robust progress in its Phase 3 OVATION 3 study for IMNN-001, a treatment for advanced ovarian cancer. The company reported positive advancements, including the dosing of the first patient and a strong push towards activating additional clinical sites. A notable highlight was the introduction of a 15% stock dividend, reflecting confidence in its clinical programs and a commitment to shareholder value. Additionally, data from a recent Phase 2 study presented at ASCO reinforced the promising efficacy of IMNN-001 in improving survival rates.
Read more →IMNNIMUNON Announces First Patient Dosed in Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
IMUNON, Inc. has announced the dosing of the first patient in its Phase 3 OVATION 3 Study of IMNN-001, a DNA-mediated immunotherapy aimed at treating newly diagnosed advanced ovarian cancer. The study will evaluate IMNN-001 in combination with standard chemotherapy to assess its safety and efficacy. Positive data from earlier trials suggest that IMNN-001 may significantly improve overall survival and other critical endpoints for patients with limited treatment options. The company is optimistic about furthering patient recruitment and expanding the trial in upcoming months.
Read more →IMNN▲ +8.9%on this newsshared move
IMUNON to Hold Second Quarter 2025 Financial Results and Business Update Conference Call on Tuesday, August 5, 2025
IMUNON, Inc. will host a conference call on August 5, 2025, to discuss its financial results for Q2 2025 and provide updates on its clinical development programs. Key among these is IMNN-001, a DNA-based immunotherapy in a Phase 3 trial aimed at treating advanced ovarian cancer. The company has also completed a first-in-human study of its COVID-19 booster vaccine, IMNN-101. The results of these developments will be reported along with financial details during the call.
Read more →IMNNIMUNON Announces Stock Dividend Boosting Shareholder Value Stock Dividend Reflects Company's Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders LAWRENCEVILLE, N.J.
IMUNON, Inc. announced a 15% stock dividend, reflecting the company's confidence in its Phase 3 study and long-term growth potential. The stock dividend will distribute approximately 448,000 additional shares and is indicative of the company’s commitment to share value with shareholders. IMUNON’s lead program, IMNN-001, continues to advance in clinical trials, offering promising data for advanced ovarian cancer treatments. This action aims to align the interests of shareholders with the company's innovative growth strategy.
Read more →IMNN▼ -15.8%on this newsshared move
IMUNON Announces Reverse Stock Split LAWRENCEVILLE, N.J.
IMUNON, Inc. announced a reverse stock split of its common stock at a ratio of 1-for-15, effective July 25, 2025, following stockholder approval. The measure aims to meet Nasdaq's minimum bid price requirements for continued listing. As a result of the split, outstanding shares will decrease significantly, though shareholder percentage interest will remain largely unchanged. The company's ongoing clinical programs include a DNA-based therapy for advanced ovarian cancer and a COVID-19 booster vaccine.
Read more →IMNN▼ -15.8%on this newsshared move
IMUNON Announces Reverse Stock Split
IMUNON, Inc. announced a reverse stock split at a ratio of 1-for-15 effective July 25, 2025, approved by stockholders to maintain its listing on the Nasdaq Capital Market. This action will reduce the number of outstanding shares from approximately 31.8 million to around 2.1 million shares. While this measure aims to help the company remain compliant with listing requirements, it highlights existing concerns regarding the stock's performance. The company continues to focus on advancing its DNA-mediated immunotherapy portfolio, which includes treatments for advanced ovarian cancer and COVID-19.
Read more →IMNNIMUNON Granted Continued Listing Extension by Nasdaq to Complete Compliance Plan
IMUNON, Inc. has received an extension from the Nasdaq Hearing Panel to complete its compliance plan, allowing the company to maintain its listing. The extension was granted after a review of IMUNON's compliance strategies, which have already met the Equity Rule through recent fundraising. The company is committed to implementing its plan in a timely manner and may request additional time if necessary. Its CEO expressed confidence in the plan's potential to create long-term value for shareholders.
Read more →IMNN▲ +8.1%on this news
IMUNON Submits Plan in Consultation with the Exchange to Ensure Compliance with Nasdaq’s Listing Requirement, Anticipates Additional Compliance Period
IMUNON, Inc. has submitted a compliance plan to Nasdaq to address minimum bid price and stockholders' equity requirements essential for continued listing. The plan follows a request for a hearing, aiming for a 180-day extension to achieve compliance. The company’s financial status has improved, with equity surpassing $3 million. IMUNON continues to advance its lead clinical program, IMNN-001, and is optimistic about future milestones in its immunotherapy development.
Read more →IMNN▼ -11.5%on this news
IMUNON Presents Positive Phase 2 Translational Data of IMNN-001 in Advanced Ovarian Cancer at ESMO Gynaecological Cancers Congress 2025
IMUNON, Inc. has presented promising Phase 2 translational data for its investigational therapy IMNN-001 at the ESMO Gynaecological Cancers Congress 2025. The data indicates substantial increases in the levels of interleukin-12 and other key anti-cancer cytokines in the tumor microenvironment of patients with advanced ovarian cancer. IMNN-001, in combination with standard chemotherapy, showed a favorable safety profile and positive overall survival results, leading to the advancement into a pivotal Phase 3 trial. The therapy aims to enhance the immune response specifically at the tumor site, offering hope for improved outcomes in this challenging cancer type.
Read more →IMNNIMUNON Announces PlaCCine DNA Vaccine Technology Abstract Selected for Oral Presentation at 10th International Conference on Vaccines Research & Development™
IMUNON, Inc. announced that its investigational DNA plasmid vaccine, IMNN-101, will be presented at the 10th International Conference on Vaccines Research & Development. Phase 1 trial results highlight the vaccine's durability, temperature stability, and a three-fold increase in antibody titers compared to baseline at six months. The company is actively seeking strategic partnerships to fund the advancement of its PlaCCine technology for COVID-19 and other infectious agents. IMNN-101 has shown good safety and tolerability, indicating potential as a competitive alternative to mRNA vaccines.
Read more →IMNN▼ -17.6%on this news
IMUNON to Present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12th
Imunon, Inc. (IMNN) will present at the Zacks SCR Life Sciences Virtual Investor Forum on June 12, 2025. The company's President and CEO, Stacy Lindborg, will share insights on its DNA-mediated immunotherapy, particularly the advanced clinical program IMNN-001 aimed at treating ovarian cancer. Imunon is also working on a COVID-19 booster vaccine, further advancing its innovative treatments. Investors are encouraged to participate live or access a recorded version of the presentation afterward.
Read more →IMNN▼ -23.9%on this news· ran to -42% by day 3shared move
IMUNON Announces Data Presented at ASCO Reinforces Unprecedented Overall Survival in Ovarian Cancer Phase 2 Study
IMUNON, Inc. announced promising results from its Phase 2 OVATION 2 Study for IMNN-001, an immunotherapy targeting advanced ovarian cancer. The study showed significant improvements in overall survival and progression-free survival compared to standard treatment, with a favorable safety profile. Data were presented at the ASCO 2025 Annual Meeting, highlighting the potential of IMNN-001 to transform treatment for patients, especially those with BRCA1 and BRCA2 mutations. The company plans to advance to a pivotal Phase 3 trial based on these results.
Read more →IMNNIMUNON CEO RECAPS A YEAR OF CLINICAL ACHIEVEMENT AND SOLID FUNDAMENTALS
IMUNON, Inc. has reported significant progress in its clinical trials, particularly with its lead candidate IMNN-001 for ovarian cancer. The Phase 2 OVATION 2 Study highlighted a substantial increase in median overall survival compared to standard treatments. The upcoming Phase 3 OVATION 3 Study is anticipated to validate these findings further. IMUNON also emphasized its strong financial performance and the potential to meet NASDAQ listing requirements, which positions the company for promising future growth.
Read more →IMNN▼ -33%on this newsshared move
IMUNON Closes Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules
IMUNON, Inc. has completed a private placement raising $3.25 million by selling 7,222,223 shares and short-term warrants. These warrants could potentially generate an additional $6.5 million if fully exercised. The funds will be used for working capital and corporate purposes. The securities offered are not registered under the Securities Act, necessitating careful compliance with federal regulations regarding their sale.
Read more →IMNN▲ +95.7%on this news· ran to +115% by day 3shared move
IMUNON Invited to Present Translational Data in Supporting Remarkable Phase 2 Ovarian Cancer Survival Results at ESMO Gynaecological Cancers Congress 2025
IMUNON, Inc. announced that data from its Phase 2 OVATION 2 Study on the immunotherapy IMNN-001 will be presented at the ESMO Gynaecological Cancers Congress 2025. The study showcases promising results regarding the safety and efficacy of IMNN-001 in improving survival outcomes for women with advanced ovarian cancer. This presentation follows an upcoming oral presentation at the ASCO Annual Meeting and highlights continuous improvements in overall and progression-free survival. With significant interest from the scientific community, IMUNON is set to advance its pivotal Phase 3 trial.
Read more →IMNN▲ +179.2%on this news· ran to +446% by day 1shared move
IMUNON Announces 2025 ASCO Annual Meeting Oral Presentation Highlighting Unprecedented Survival Data from Phase 2 Trial of IMNN-001 in Treatment of Newly Diagnosed Advanced Ovarian Cancer
IMUNON, Inc. has announced positive results from its Phase 2 OVATION 2 Study of IMNN-001, which demonstrates significant improvements in overall and progression-free survival for patients with newly diagnosed advanced ovarian cancer. These findings will be presented at the 2025 ASCO Annual Meeting and have been published in Gynecologic Oncology. Following this encouraging data, IMUNON has initiated the Phase 3 OVATION 3 Study to further evaluate IMNN-001's efficacy. The results indicate that IMNN-001 could provide an extended lifespan for patients compared to current standard treatments.
Read more →IMNN▲ +179.2%on this news· ran to +446% by day 1shared move
IMUNON Announces Up To $9.75 Million Private Placement Priced At-The-Market Under Nasdaq Rules $3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full o
IMUNON, Inc. has announced a private placement expected to yield up to $9.75 million, consisting of $3.25 million upfront and potential additional proceeds of $6.5 million from short-term warrants. The offering, priced at $0.45 per share, will close on or about May 27, 2025, pending customary closing conditions. The funds will be used for working capital and general corporate purposes, supporting the company's development of its innovative DNA-mediated immunotherapy products. However, there are uncertainties regarding shareholder approval and market conditions that could impact the offering.
Read more →IMNNIMUNON Announces Withdrawal of Form S-1 Registration Statement
IMUNON, Inc. has announced the withdrawal of its Form S-1 Registration Statement with the SEC, halting its plans for a public offering. This decision comes after the registration had not been declared effective and no securities were sold. The company continues to focus on its DNA-mediated immunotherapy programs, including the development of its lead therapy IMNN-001 for advanced ovarian cancer. Despite this setback, IMUNON remains committed to advancing its innovative treatments and leveraging its DNA technology.
Read more →IMNN▼ -8.4%on this news· ran to -28% by day 3
IMUNON Announces Six-Month Data Showing Durability of Protection for Next-Generation DNA Vaccine Platform in Phase 1 Clinical Trial in COVID-19
IMUNON, Inc. announced positive results from a Phase 1 trial of its IMNN-101 DNA vaccine against COVID-19, showing a durable immune response at six months post-vaccination. The trial included 24 healthy volunteers, revealing significant increases in neutralizing antibody levels, particularly in higher dose cohorts. The results also suggest advantages of the PlaCCine platform in terms of vaccine stability and manufacturing ease compared to mRNA vaccines. IMUNON is exploring further development opportunities for its vaccine technology.
Read more →IMNNIMUNON Reports First Quarter 2025 Financial Results and Provides Business Update First site initiated for Phase 3 OVATION 3 study of IMNN-001 in treatment of newly diagnosed advanced ovarian cancer New data from Phase 2
IMUNON, Inc. has reported its financial results for Q1 2025 and provided an update on its business activities. The company has initiated the first site for its Phase 3 OVATION 3 study of IMNN-001, aimed at treating newly diagnosed advanced ovarian cancer. Notably, data from the previously conducted Phase 2 OVATION 2 study has been accepted for oral presentation at the upcoming 2025 ASCO Annual Meeting. The ongoing development of IMNN-001 continues to demonstrate its potential impact on treatment outcomes for patients with ovarian cancer.
Read more →IMNNIMUNON Announces First Site Initiated for Pivotal Phase 3 OVATION 3 Study of IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer
IMUNON, Inc. has initiated the first site for its pivotal Phase 3 OVATION 3 trial of the immunotherapy IMNN-001, aimed at treating newly diagnosed advanced ovarian cancer. This development follows positive overall survival results from the Phase 2 OVATION 2 study. The trial, which will include several additional sites, intends to evaluate the effectiveness and safety of IMNN-001 in conjunction with standard chemotherapy. Results from the Phase 2 study will be featured at the 2025 ASCO Annual Meeting.
Read more →IMNNIMUNON Announces Data from Phase 1/2 Trial Evaluating Intraperitoneal IMNN-001 in Combination with Neoadjuvant Chemotherapy in Newly Diagnosed Patients with Advanced Epithelial Ovarian Cancer to be Published in Gynecologic Oncology
IMUNON, Inc. has announced that data from its Phase 1/2 OVATION 2 trial will be published in the journal Gynecologic Oncology and presented at the 2025 ASCO Annual Meeting. The trial evaluates the efficacy of intraperitoneal IMNN-001 combined with chemotherapy in newly diagnosed patients with advanced epithelial ovarian cancer. The study emphasizes the potential of IMUNON's TheraPlas platform technology to develop new therapies for this challenging condition. This publication and presentation signal important advancements in the treatment landscape for ovarian cancer.
Read more →IMNNIMUNON to Hold First Quarter 2025 Financial Results and Business Update Conference Call on Monday, May 12, 2025
IMUNON, Inc. has announced it will hold a conference call on May 12, 2025, to discuss its first quarter 2025 financial results and updates on its clinical development, particularly regarding its lead program IMNN-001 for advanced ovarian cancer. The company is focused on its DNA-mediated immunotherapy approach, which has shown promise in previous trials, including a Phase 2 study. Additionally, IMUNON has made progress in developing its COVID-19 booster vaccine. Participants can join the call live or access a recording afterward.
Read more →IMNNIMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting
IMUNON, Inc. announced that an abstract featuring promising Overall Survival data from the OVATION 2 Study of its treatment IMNN-001 has been accepted for oral presentation at the 2025 ASCO Annual Meeting. The meeting is scheduled to take place from May 30 to June 3, 2025, in Chicago. In addition, IMUNON has initiated site activations for its Phase 3 OVATION 3 clinical trial after aligning its protocol with the FDA. IMNN-001 is an IL-12 DNA immunotherapy specifically targeting newly diagnosed advanced ovarian cancer.
Read more →IMNN▼ -6.1%on this news
IMUNON Finalizes Phase 3 Study Design with FDA for IMNN-001 in Newly Diagnosed Advanced Ovarian Cancer First and only immunotherapy to show meaningful overall survival benefit in a Phase 2 trial in patients with advanced
IMUNON, Inc. has finalized its Phase 3 study design for IMNN-001, an immunotherapy treatment for newly diagnosed advanced ovarian cancer, following alignment with the FDA. This pivotal trial, named OVATION 3, is based on promising Phase 2 results that demonstrated meaningful overall survival benefits. The company is currently initiating trial sites and plans to enroll participants swiftly. IMNN-001 is noteworthy as the first immunotherapy to exhibit a clinically effective response in advanced ovarian cancer treatment, aiming to improve patient outcomes significantly.
Read more →IMNNIMUNON Reports 2024 Financial Results and Provides Business Update Highlighting Significant Progress Towards the Initiation of a Pivotal Phase 3 Study IMNN-001 remains the first immunotherapy to achieve a meaningful over
IMUNON, Inc. reported its 2024 financial results and provided an update on its development progress toward the Phase 3 clinical trial for IMNN-001, an immunotherapy for advanced ovarian cancer. The company highlighted promising data from the Phase 2 OVATION 2 Study, demonstrating an overall survival benefit for patients treated with IMNN-001. With the trial enrollment for IMNN-001 set to begin in the first quarter of 2025, IMUNON is optimistic about the treatment's potential impact in a field with limited options. Additionally, the safety profile of the drug remains favorable, with no serious adverse events reported.
Read more →IMNNIMUNON Announces New Immunogenicity Data from Phase 1 Clinical Trial of Its DNA Vaccine in Treatment of COVID-19
IMUNON, Inc. announced promising results from its Phase 1 clinical trial of IMNN-101, a DNA vaccine targeting the Omicron XBB.1.5 variant of SARS-CoV-2. The trial demonstrated a significant increase in neutralizing antibody titers over four weeks and confirmed the vaccine's safety, showing no serious adverse effects. Additionally, the vaccine indicated cross-reactivity against newer variants and is viewed as a potential next-generation immunization option with advantages over existing mRNA vaccines. The company anticipates interest from potential partners following these encouraging results.
Read more →IMNNIMUNON to Hold 2024 Financial Results and Business Update Conference Call on Thursday, February 27, 2025
IMUNON, Inc. announced it will report its 2024 financial results before the market opens on February 27, 2025. A conference call will follow to discuss these results and provide a business update. The company is advancing several innovative DNA-mediated immunotherapy treatments, including IMNN-001 for advanced ovarian cancer and a COVID-19 booster vaccine. IMUNON continues to explore opportunities for business development to strengthen its resources.
Read more →IMNNIMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
IMUNON, Inc. announced promising results from the Phase 2 OVATION 2 Study of its investigational immunotherapy IMNN-001 for advanced ovarian cancer. The drug demonstrated a significant 20% increase in IL-12 levels at a higher dose, while maintaining a favorable safety profile without serious adverse events. More than one-third of patients treated saw improvements in overall survival, prompting the company to advance into a pivotal Phase 3 trial. This data reinforces the efficacy and safety of IMNN-001 in combination with standard chemotherapy for treating advanced ovarian cancer.
Read more →IMNNIMUNON Appoints Douglas V. Faller, M.D., Ph.D., as Chief Medical Officer Dr. Faller joins IMUNON with more than 30 years of industry, academic and laboratory experience, with specialized expertise in oncology and immunol
IMUNON, Inc. has appointed Douglas V. Faller, M.D., Ph.D., as its new Chief Medical Officer, effective February 18, 2025. Dr. Faller brings over 30 years of experience in biopharma, particularly in oncology and immunology, which is expected to enhance the company's clinical strategy and advance its lead program, IMNN-001, for the treatment of advanced ovarian cancer. The company is gearing up for the Phase 3 pivotal trial of IMNN-001, following promising results from previous studies. This strategic leadership change aims to drive growth and bolster their innovative non-viral DNA-based immunotherapy pipeline.
Read more →IMNNIMUNON Announces Positive CMC Meeting with FDA for IMNN-001 in Treatment of Advanced Ovarian Cancer
IMUNON, Inc. announced a positive outcome from a Type C Chemistry, Manufacturing, and Controls meeting with the FDA regarding its IMNN-001 immunotherapy for advanced ovarian cancer. The meeting aimed to establish alignment on CMC topics to support the upcoming Phase 3 pivotal trial set to begin in early 2025. The FDA approved the company's manufacturing processes and potency assay, which are crucial for future commercialization. IMUNON's work could significantly contribute to treatment options for women diagnosed with this severe form of cancer.
Read more →IMNNIMUNON Announces Continued Strong Improvement in Overall Survival Data from Randomized Phase 2 OVATION 2 Study of IMNN-001
IMUNON has reported positive results from its Phase 2 OVATION 2 Study of IMNN-001, showing an increase in median overall survival for women with advanced ovarian cancer, from 11 to 13 months. The study also revealed that 62% of patients receiving the treatment survived more than 36 months. The company plans to launch a Phase 3 pivotal trial for IMNN-001 in the first quarter of 2025, highlighting the ongoing development of this promising immunotherapy. Safety data remains encouraging, with no serious adverse events reported.
Read more →IMNNIMUNON Announces Results from its End-of-Phase 2 Meeting with the FDA for its Lead IMNN-001 Clinical Program in Advanced Ovarian Cancer
IMUNON, Inc. has received positive feedback from the FDA regarding its Phase 3 trial strategy for IMNN-001, an IL-12 immunotherapy aimed at treating advanced ovarian cancer. The company plans to submit the final protocol by December 2024, with an initiation of the trial expected in Q1 2025. IMNN-001 has shown promising results in the Phase 2 OVATION 2 Study, improving overall survival rates by approximately one year when combined with standard chemotherapy. This development marks a significant step toward addressing the medical needs of patients with advanced ovarian cancer.
Read more →IMNN▼ -12.3%on this news
IMUNON Reports Third Quarter 2024 Financial Results and Provides Business Updates Conference call today at 11:00 a.m.
IMUNON, Inc. reported its third quarter 2024 financial results and provided business updates on its clinical development of IMNN-001 for advanced ovarian cancer. The company shared significant progress, including an overall survival improvement compared to standard treatment and plans for a Phase 3 study set to commence in early 2025. Additional data from the OVATION 2 Study is being presented at a key oncology meeting, underlining the potential of their product. Despite a reported loss this quarter, IMUNON remains encouraged by the interest in their findings and is positioned for future growth.
Read more →IMNN▼ -12.3%on this news
IMUNON Presents Positive Data from Phase 2 OVATION 2 Clinical Trial of IMNN-001 in Advanced Ovarian Cancer at SITC 39th Annual Meeting
IMUNON, Inc. presented positive results from its Phase 2 OVATION 2 clinical trial of IMNN-001, an investigational therapy for advanced ovarian cancer, at the SITC Annual Meeting. The study showed a 35% improvement in overall survival and a 25% improvement in progression-free survival compared to standard chemotherapy. Treatment was generally well tolerated, with no serious immune-related adverse events reported. IMUNON plans to initiate a Phase 3 pivotal trial in Q1 2025 to further assess the efficacy of IMNN-001.
Read more →IMNNIMUNON to Hold Third Quarter 2024 Financial Results and Business Update Conference Call on Thursday, November 7, 2024
IMUNON, Inc. will hold a conference call on November 7, 2024, to discuss its third-quarter financial results and updates on its clinical programs. The call will focus on its lead candidate IMNN-001, a DNA-based immunotherapy for advanced ovarian cancer, and the PlaCCine modality for next-generation vaccines. IMUNON aims to leverage its DNA technology to enhance treatment options for patients. The call will be accessible via dial-in or live webcast.
Read more →IMNNIMUNON to Present Phase 2 Data of IMNN-001 in Treatment of Newly Diagnosed Ovarian Cancer at SITC 39th Annual Meeting
IMUNON, Inc. announced that new clinical data from its Phase 2 OVATION 2 Study of IMNN-001 will be presented at the SITC 39th Annual Meeting. The company is also preparing for an End-of-Phase 2 meeting with the FDA to discuss advancing IMNN-001 to a Phase 3 trial anticipated to begin in Q1 2025. Key findings from the study demonstrate an 11.1-month improvement in median overall survival for patients treated with IMNN-001 compared to those receiving standard care. These developments reflect the growing encouragement surrounding the investigational therapy for advanced ovarian cancer.
Read more →IMNN▼ -5.5%on this news
IMUNON Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) LAWRENCEVILLE, N.J. (
IMUNON, Inc. (NASDAQ: IMNN) has reported an inducement grant involving stock options as part of their recruitment strategy. The company granted stock options to two new hires, totaling 110,000 shares, under NASDAQ Listing Rule 5635(c)(4). This initiative aims to attract talented professionals and enhance the company's operations as they advance their clinical-stage immunotherapy programs, notably in the treatment of ovarian cancer and COVID-19. Moving forward, IMUNON continues to leverage its innovative DNA technology to provide solutions for various diseases.
Read more →IMNNIMUNON to Host R&D Day on September 18th
IMUNON, Inc. will hold an R&D Day on September 18th in New York City, focusing on the potential of its DNA-mediated immunotherapy, IMNN-001, to treat advanced ovarian cancer. The event follows positive topline data from the Phase II OVATION 2 Study, which indicated an 11.1 month increase in median overall survival. Attendees will have the chance to engage with thought leaders and discuss the study's implications for future Phase 3 trials. Virtual participation will also be available for those who cannot attend in person.
Read more →IMNN▼ -11.4%on this news
IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update
IMUNON, Inc. has reported positive topline results from its Phase 2 OVATION 2 Study, revealing significant improvements in overall survival for advanced ovarian cancer patients treated with IMNN-001. The company plans to advance to a Phase 3 pivotal study in early 2025 following successful discussions with the FDA. Furthermore, IMUNON is in the early stages of a Phase 1 clinical trial for its seasonal COVID-19 booster candidate, IMNN-101, which aims to elicit a robust immune response. Financially, IMUNON has demonstrated a reduction in net losses compared to the previous year.
Read more →IMNN▼ -11.4%on this news
Final AUGUST 12, 2024 IMUNON Reports Second Quarter 2024 Financial Results and Provides a Business Update Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J. (
IMUNON, Inc. reported its financial results for the second quarter of 2024, highlighting positive topline results from its Phase 2 OVATION 2 Study for advanced ovarian cancer. The study demonstrated an 11.1 month increase in median overall survival for IMNN-001 compared to standard care. The company also raised $9.3 million to support clinical developments and plans to pursue a Phase 3 study. However, IMUNON reported a net loss of $4.8 million during the quarter.
Read more →IMNN▼ -7.8%on this news
IMUNON to Hold Second Quarter 2024 Financial Results and Business Update Conference Call on Wednesday, August 14, 2024
IMUNON, Inc. will hold a conference call on August 14, 2024, to discuss its second quarter financial results and provide updates on its clinical development programs. The highlight includes the Phase 2 advancement of IMNN-001, a DNA-based immunotherapy for ovarian cancer. The company continues to innovate within the realm of DNA-mediated therapies, focusing on harnessing natural immune responses to tackle various diseases. Additionally, they aim to strengthen their financial position through business development opportunities.
Read more →IMNN▼ -59.3%on this news
IMUNON Announces $10 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules LAWRENCEVILLE, N.J. (
IMUNON, Inc. announced a registered direct offering of its common stock priced at-the-market under Nasdaq rules, expecting to raise $10 million. The offering includes unregistered warrants that accompany the stock purchase. The funds are intended for working capital and supporting the company's ongoing development of its DNA-mediated immunotherapy treatments, such as IMNN-001 for advanced ovarian cancer. This financing move is subject to customary closing conditions.
Read more →IMNN▲ +179%on this newsshared move
IMUNON Announces 11.1 Month Increase in Overall Survival in Patients with Newly Diagnosed, Advanced Ovarian Cancer Treated with IMNN-001 Phase 2 OVATION 2 Study of IMNN-001 administered with standard-of-care chemotherapy
IMUNON announced positive results from the Phase 2 OVATION 2 Study of IMNN-001 in patients with advanced ovarian cancer, revealing an 11.1 month increase in overall survival compared to standard-of-care treatment. The study showed a hazard ratio of 0.74, indicating a 35% improvement in survival outcomes. Notably, patients receiving at least three doses of IMNN-001 experienced a median overall survival increase of 15.7 months. IMUNON plans to initiate a registrational study in early 2025 to assess the potential for IMNN-001 to become part of the standard treatment for ovarian cancer.
Read more →IMNNIMUNON to Report Topline Results from the Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer Tomorrow
IMUNON, Inc. is set to report topline results from its Phase 2 OVATION 2 study with IMNN-001, targeting advanced ovarian cancer. The announcement will take place on July 30, 2024, at 8:00 a.m. Eastern time, followed by a conference call at 8:30 a.m. to discuss the findings. IMNN-001 is designed as a DNA-based immunotherapy that instructs the body to produce cancer-fighting molecules directly at the tumor site, showcasing the company's innovative approach to treatment. IMUNON is deeply engaged in developing effective therapies using its unique DNA technology, positioning itself in the competitive biotech landscape.
Read more →IMNNIMUNON Announces Database Lock for Phase 2 OVATION 2 Study with IMNN-001 in Advanced Ovarian Cancer
IMUNON, Inc. has announced the successful database lock for its Phase 2 OVATION 2 Study, which assesses the safety and efficacy of its immunotherapy IMNN-001 in patients with advanced ovarian cancer. The study has reached key endpoints, including median overall survival and progression-free survival, with results anticipated by the end of July 2024. The independent statistical analysis plan will evaluate the trial data to support the design of a potential Phase 3 trial. This achievement represents a critical step in IMUNON's mission to provide innovative treatments for patients facing advanced ovarian cancer.
Read more →IMNN▲ +7.3%on this news
IMUNON Reports First Quarter 2024 Financial Results and Provides Business Update Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J. (
IMUNON, Inc. has reported its financial results for Q1 2024 and provided updates on its clinical trials, particularly regarding the promising IMNN-001 therapy for ovarian cancer. The company anticipates key data readouts from ongoing studies in mid-2024, which could significantly influence treatment outcomes. Additionally, they have received FDA approval for a Phase 1 trial of their DNA-based COVID-19 booster vaccine, IMNN-101. The recent appointment of Stacy R. Lindborg as CEO is seen as a strategic enhancement to the company's leadership as it navigates these critical clinical developments.
Read more →IMNN▲ +7.3%on this news
IMUNON Announces Site Activation for IMNN-101 Phase 1 Vaccine Study
IMUNON, Inc. announced the activation of the first site for its Phase 1 study of the IMNN-101 vaccine, aimed at providing protection against a specific variant of SARS-CoV-2. Enrollment is now open, with topline results expected by year-end. The study will evaluate the safety and efficacy of the vaccine using the company's innovative PlaCCine platform, which has shown promising preclinical results. A second site in Boston is expected to be activated soon, furthering the progression of this clinical trial.
Read more →IMNN▲ +17.2%on this newsshared move
IMUNON Appoints Director Dr. Stacy R. Lindborg as President and CEO Assumes leadership role as Company anticipates multiple near-term clinical milestones Brings extensive leadership and experience in drug development and
IMUNON, Inc. has announced the appointment of Dr. Stacy R. Lindborg as President and CEO, effective May 13, 2024. Dr. Lindborg, who has been on the company's board since 2021, brings nearly 30 years of experience in the pharmaceutical and biotech sectors. Her leadership comes at a critical time as IMUNON is expecting key clinical milestones, including topline results from the Phase 2 OVATION 2 Study for advanced ovarian cancer and Phase 1 data for a COVID-19 vaccine by the end of the year.
Read more →IMNNIMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
IMUNON, Inc. (NASDAQ: IMNN) will host a conference call on May 13, 2024, to discuss its first-quarter financial results and provide updates on its clinical development programs. Key focuses include the Phase 2 clinical trial of IMNN-001, a DNA-based therapy for advanced ovarian cancer, and the launch of a first-in-human study for a COVID-19 booster vaccine. The conference call will also cover the company's proprietary DNA technology platforms, TheraPlas® and PlaCCine®.
Read more →IMNNIMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
IMUNON, Inc. has received FDA clearance to initiate a Phase 1 clinical trial for its DNA-based COVID-19 booster vaccine, IMNN-101. The trial aims to evaluate the safety, tolerability, and immunogenicity of the vaccine in healthy adults, with patient enrollment expected to start in Q2 2024. IMNN-101 leverages the company's proprietary PlaCCine platform, which may demonstrate superior performance compared to existing mRNA vaccines. The trial will involve 24 subjects across two clinical sites, focusing on protection against the SARS-CoV-2 Omicron XBB1.5 variant.
Read more →IMNN▲ +6.2%on this news
IMUNON Reports Compliance with Nasdaq Listing Requirements LAWRENCEVILLE, N.J. (
IMUNON, Inc. has announced that it has regained compliance with Nasdaq's minimum bid price listing requirements as of April 10, 2024, after meeting the $1.00 closing bid price for ten consecutive trading days. Executive Chairman Michael H. Tardugno emphasized the importance of this compliance in advancing the company's technologies. IMUNON is set to report topline results from the OVATION 2 Study in mid-2024 and is preparing to initiate a Phase 1 clinical study for a COVID-19 booster vaccine. The company's ongoing projects focus on innovative immunotherapy and DNA-based vaccine development.
Read more →IMNN▲ +17.1%on this news· ran to +38% by day 1
IMUNON Reports 2023 Financial Results and Provides Business Update Conference Call Begins Today at 10:00 a.m. Eastern Time LAWRENCEVILLE, N.J. (
IMUNON, Inc. reported its 2023 financial results and provided an update on several clinical development programs, including IMNN-001 for advanced ovarian cancer. Interim data from the OVATION 2 Study showed a 30% delay in disease progression and a nine-month improvement in overall survival with IMNN-001. The company also advanced its PlaCCine platform, demonstrating promising preclinical data for next-generation vaccines. Key milestones for 2024 include reporting final results from the OVATION 2 Study and beginning a Phase 1 clinical trial for a COVID-19 booster vaccine.
Read more →IMNNIMUNON Receives $1.3 Million from Sale of its New Jersey Net Operating Losses
IMUNON, Inc. secured $1.3 million in cash proceeds by selling unused New Jersey net operating losses through the state’s NJEDA program. This funding is designed to bolster the company's balance sheet and support its clinical development programs. IMUNON aims to leverage this non-dilutive capital to advance its innovative treatments in DNA-mediated immuno-oncology and next-generation vaccines. The company continues to develop its lead program, IMNN-001, a DNA-based immunotherapy for treating advanced ovarian cancer, and is entering studies for a COVID-19 booster vaccine.
Read more →IMNN▲ +6.4%on this news· ran to +50% by day 3shared move
IMUNON to Hold 2023 Financial Results and Business Update Conference Call on Thursday, March 28, 2024
IMUNON, Inc. will host a conference call on March 28, 2024, to discuss its financial results for 2023 and provide updates on its clinical programs. The company is focusing on its DNA-mediated immunotherapy, IMNN-001, currently in Phase 2 trials for advanced ovarian cancer, and its PlaCCine technology for vaccine development. Participants can join via phone or listen to a live webcast. IMUNON's approach integrates innovative immunotherapy methods to tackle complex diseases.
Read more →IMNN▼ -6.3%on this news
IMUNON Files IND Application to Begin Human Testing of IMNN-101
IMUNON, Inc. has submitted an Investigational New Drug (IND) application to the FDA for its DNA-based vaccine IMNN-101, aimed at a Phase 1 clinical study as a seasonal booster against COVID-19. Following FDA approval, enrollment for the human study is anticipated to start in Q2 2024. The study will focus on assessing vaccine safety, tolerability, and immune response, leveraging preclinical evidence that suggests potential superiority over traditional mRNA vaccine approaches. This marks a significant step for IMUNON as it seeks to demonstrate the efficacy of its PlaCCine platform in combating COVID-19 variants.
Read more →IMNN▼ -6%on this newsshared move
IMUNON Announces Leadership Change Executive Chairman to lead day-to-day operations, active search underway for CEO successor. Timing of upcoming milestones for key programs remains unchanged. LAWRENCEVILLE, N.J. (
IMUNON, Inc. has announced a leadership change following the resignation of Dr. Corinne Le Goff as President and CEO, effective March 15, 2024. Michael H. Tardugno, the Executive Chairman, will lead day-to-day operations while a search for a new CEO begins. The company assures that the timing for key program milestones remains unchanged, with important studies on the horizon, including preparations for a Phase 1 COVID-19 booster vaccine and updates on ovarian cancer treatment data expected soon.
Read more →IMNN▼ -6%on this newsshared move
IMUNON Announces Leadership Change
IMUNON, Inc. has announced the resignation of Dr. Corinne Le Goff as President and CEO, effective March 15, 2024, as she pursues another opportunity. Michael H. Tardugno, the Executive Chairman, will lead the company in the interim while an active search for a new CEO is underway. The company affirmed that the timeline for its key programs remains unchanged, including plans for a Phase 1 study of its COVID-19 booster vaccine and topline data from a study in advanced ovarian cancer. IMUNON plans to share financial results and provide further updates in late March 2024.
Read more →IMNNIMUNON Appoints Dr. Sebastien Hazard as Chief Medical Officer and Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) Accomplished pharmaceutical and biotechnology executive to lead IMUNON's clinical programs i
IMUNON, Inc. has appointed Dr. Sebastien Hazard as Chief Medical Officer, effective December 11, 2023. With nearly 25 years of experience in drug development, Dr. Hazard will oversee the company's clinical programs, particularly in ovarian cancer and infectious diseases. This appointment comes as IMUNON prepares to unveil topline data from an important study involving their IMNN-001 immunotherapy in 2024. Additionally, the company announced an inducement option for stock grants related to Dr. Hazard's employment.
Read more →IMNNIMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update Advances Non-Viral DNA-Mediated Cancer Immunotherapy and Next-Generation Vaccine Programs, with More Potent and Durable Immunity, with Mu
IMUNON, Inc. has reported strong progress in its third quarter financial results and business developments. The company is advancing its IMNN-001 immunotherapy in ovarian cancer, demonstrating promising interim data that indicates improved progression-free survival and overall survival. Additionally, IMUNON is moving forward with clinical trials for a COVID-19 vaccine and has formed collaborations to enhance its immunotherapy research. Financially, the company reported $19.5 million in cash, supporting its ongoing projects.
Read more →IMNNIMUNON’s VP of R&D to Present at the Vaccines Summit-2023
IMUNON, Inc. has announced that Dr. Jean Boyer, VP of R&D, will showcase their vaccine development at Vaccines Summit-2023. The presentation will focus on updated data regarding the PlaCCine SARS-CoV-2 DNA vaccine, emphasizing its ability to maintain robust immune responses for up to 14 months and significantly reduce viral loads in study subjects. With promising results from both mouse and primate studies, IMUNON aims to position PlaCCine as a viable next-generation vaccine solution, particularly in addressing global health challenges.
Read more →IMNNIMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023
IMUNON, Inc. will hold a conference call on November 14, 2023, to discuss its third-quarter financial results and updates on its clinical pipeline. The company is focusing on its lead candidate, IMNN-001, a DNA-based immunotherapy for advanced ovarian cancer, currently in Phase 2 trials. Additionally, IMUNON is conducting preclinical studies on a range of therapeutic candidates, including a COVID-19 booster and a LASSA virus treatment. This call is expected to provide insights into the company's ongoing research and development efforts.
Read more →IMNN▲ +7.5%on this news
IMUNON’s Chief Science Officer to Present at the 3rd International Vaccines Congress
IMUNON, Inc. announced that its Chief Science Officer, Dr. Khursheed Anwer, will present at the 3rd International Vaccines Congress. The presentation will showcase the advantages of IMUNON’s PlaCCine technology over existing vaccines, including better durability and immune response. The focus will be on IMNN-101, which targets the SARS-CoV-2 Omicron variant, with plans for an Investigational New Drug application and Phase 1 trial in early 2024. Dr. Anwer's presentation will underscore the technology’s efficacy against various viruses and its potential for commercial application.
Read more →IMNNIMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations
Dr. Corinne Le Goff, CEO of IMUNON, will participate in a pandemic preparedness panel at the United Nations that focuses on lessons learned from the pandemics of 1889 and 2019. The panel is organized by the Foreign Policy Association and features various experts discussing the implications of past pandemics on future preparedness. IMUNON is actively involved in developing new vaccine technology, including a DNA-based platform, aimed at combating infectious diseases and cancer. This participation aligns with the company's commitment to innovative healthcare solutions.
Read more →IMNNIMUNON Announces First Patient enrolled in Phase 1/2 Clinical Trial of IMNN-001 in Combination with bevacizumab in Advanced Ovarian Cancer
IMUNON, Inc. has commenced a Phase 1/2 clinical trial with the first patient enrolled to evaluate IMNN-001 combined with bevacizumab for advanced ovarian cancer. This trial aims to assess its effect on minimal residual disease and involves 50 patients undergoing frontline therapy. Initial data from the trial, along with insights into immunogenomic features of ovarian cancer, are expected within the next three years. The trial is part of a collaborative effort under the Break Through Cancer initiative, aiming to innovate treatment approaches in oncology.
Read more →IMNNIMUNON Appoints Dr. Patrick Ott to its Scientific Advisory Board
IMUNON, Inc. has appointed Dr. Patrick Ott to its Scientific Advisory Board, enhancing its leadership in immuno-oncology. Dr. Ott, a prominent researcher at the Dana-Farber Cancer Institute, will lend his expertise to develop IMUNON's FixPlas™ and IndiPlas™ modalities. This strategic addition is aimed at advancing the company’s portfolio of DNA-mediated immunotherapies and personalized cancer vaccines. With ongoing preclinical work in melanoma, IMUNON is poised to make significant contributions to cancer treatment.
Read more →IMNN▼ -6.9%on this news
IMUNON Reports Interim Progression-Free Survival and Overall Survival Data in Phase 1/2 OVATION 2 Study in Advanced Ovarian Cancer
IMUNON reported interim results from its Phase 1/2 OVATION 2 study, showing promising trends in progression-free survival and overall survival for patients treated with the IMNN-001 immunotherapy combined with neoadjuvant chemotherapy. The study enrolled 110 patients, with initial findings showing a 33% delay in disease progression and an approximate 9-month improvement in overall survival over the control group. Subgroup analysis suggests that patients receiving both IMNN-001 and PARP inhibitors may benefit significantly. Full results are expected by mid-2024.
Read more →IMNNIMUNON Releases Enterprise Video Highlighting the Company’s Mission, Vision, Values, Breakthroughs and Technologies
IMUNON, Inc. has released an enterprise video detailing its mission, vision, and technological advancements as part of its newly relaunched website. The video presents insights into the company's cGMP manufacturing facility in Huntsville, Alabama, and highlights its focus on developing DNA-mediated immunotherapy and next-generation vaccines. CEO Dr. Corinne Le Goff expressed pride in showcasing the company's potential impact on treating various diseases through innovative treatments. IMUNON is committed to advancing immunotherapy, with a particular focus on oncology and infectious diseases, leveraging its proprietary technologies.
Read more →IMNNIMUNON Reminds Investors of its Virtual R&D Day Tomorrow at 4:00 p.m. ET
IMUNON, Inc. is reminding investors about its Virtual R&D Day scheduled for September 14 at 4:00 p.m. ET. The event will showcase presentations from the company's executive management and leading experts in immuno-oncology and vaccine development. Participants will have access to a Q&A session via the webcast. IMUNON is focused on developing innovative DNA-mediated treatments and is advancing several programs, including an immunotherapy for ovarian cancer currently in Phase 2 trials.
Read more →IMNN▼ -5.7%on this news
IMUNON to Host Virtual R&D Day on September 14th Beginning at 4:00 p.m. ET
IMUNON, Inc. will host a virtual R&D Day on September 14, featuring presentations from its executive team and key opinion leaders in immuno-oncology and vaccine development. The event will include discussions on new technologies and future vaccines. Participants will have the opportunity to engage in a Q&A session after the presentations. The company's lead clinical program is focused on a DNA-based immunotherapy for ovarian cancer currently in Phase 2 trials.
Read more →IMNNIMUNON to Participate in the H.C. Wainwright Global Investment Conference
IMUNON, Inc. will participate in the H.C. Wainwright 25th Annual Global Investment Conference from September 11-13, 2023, showcasing its innovative treatment portfolio. The company’s lead program, IMNN-001, is currently advancing through Phase 2 trials for advanced ovarian cancer. Additionally, preclinical studies are under progress for a nucleic acid vaccine targeting SARS-CoV-2. IMUNON is poised to leverage its advanced technology platforms and engage with potential investors during the conference.
Read more →IMNNIMUNON Enters into CRADA for Preclinical Studies of PlaCCine Modality in Preventive Vaccines Against Lassa Virus
IMUNON, Inc. has entered into a Cooperative Research and Development Agreement (CRADA) with the National Institute of Allergy and Infectious Diseases (NIAID) to assess two DNA-based vaccine candidates aimed at combating the Lassa virus. This three-year agreement focuses on evaluating the immunogenicity and efficacy of the PlaCCine technology in animal models, with hopes to address the significant public health threat posed by Lassa fever. Currently, there are no vaccines available for this virus, and the partnership is viewed as a crucial step in development.
Read more →IMNNIMUNON Expands Scientific Advisory Board with the Addition of Dr. Sachet Shukla
IMUNON, Inc. has expanded its scientific advisory board by appointing Dr. Sachet A. Shukla, a distinguished scientist from MD Anderson Cancer Center. Dr. Shukla will provide guidance on IMUNON's FixPlas and IndiPlas modalities aimed at developing universal and personalized cancer vaccines. His background in immunology and computational methods is expected to significantly contribute to IMUNON's ongoing preclinical research. The company is actively advancing its pipeline, including its lead clinical program for advanced ovarian cancer.
Read more →IMNNIMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update Advances Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Stron
IMUNON, Inc. reported its second quarter 2023 financial results, showcasing progress in its non-viral DNA-mediated immunotherapy and next-generation vaccine programs. The company is set to submit an IND application in early 2024 for a COVID-19 booster vaccine, guided by positive feedback from the FDA. Financially, IMUNON holds $24.1 million in cash, which will fund its operations through the next year. Recent data indicate that its PlaCCine vaccines may offer enhanced protection against pathogens compared to commercial mRNA vaccines, as they elicit robust and durable immune responses.
Read more →IMNNIMUNON to Hold Second Quarter 2023 Financial Results and Business Update Conference Call on Thursday, August 10, 2023
IMUNON, Inc. is set to hold a conference call on August 10, 2023, to discuss its financial results for the second quarter of 2023 and updates on its clinical developments. The company is focused on its lead product, IMNN-001, a DNA-based immunotherapy in Phase 2 trials for advanced ovarian cancer. Additionally, IMUNON is exploring various modalities for vaccine development, including a COVID-19 booster and personalized cancer vaccines. The company is aiming to leverage its innovative technologies to address challenging medical conditions.
Read more →IMNNIMUNON Unveils New Manufacturing Capabilities at Huntsville’s HudsonAlpha Biotech Campus
IMUNON, Inc. unveiled its new cGMP clinical materials production facility at the HudsonAlpha Institute for Biotechnology. This facility aims to enhance control over manufacturing costs for non-viral DNA-based materials used in its research and development processes. It will support clinical studies for IMUNON's infectious disease and cancer vaccine modalities. The company's leadership emphasized the importance of this capability for advancing their research and collaboration efforts, particularly in ovarian cancer treatment.
Read more →IMNNImunon Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
Imunon, Inc. announced the grant of inducement stock options and restricted stock grants as part of its hiring strategy under Nasdaq Listing Rule 5635(c)(4). The grants include 5,000 options and 1,000 restricted stock shares linked to a new employee's service. The underlying company technologies focus on innovative immunotherapy and nucleic acid vaccines. Imunon's lead clinical program, IMNN-001, targets advanced ovarian cancer and is currently in Phase 2 trials, indicating progress in its portfolio of treatments.
Read more →IMNN▲ +5.7%on this news
IMUNON CEO to Discuss Company’s Novel Non-viral DNA Therapy Option at the Mass General Brigham World Medical Innovation Forum 2023
IMUNON, Inc. announces that its CEO, Dr. Corinne Le Goff, will present at the Mass General Brigham World Medical Innovation Forum 2023. The discussion will center on the promise of IMUNON's non-viral DNA therapy option, IMNN-001, for treating advanced ovarian cancer. The panel aims to explore advancements in cell therapy for solid tumors, with a particular focus on the progress of commercializing novel immunotherapies. IMUNON is actively working to advance its unique technology platforms for cancer treatment and infectious diseases.
Read more →IMNNIMUNON’s CEO Presents Business Overview to Investors and Senior Biopharmaceutical Professionals at the BIO 2023 International Convention
At the BIO 2023 International Convention, IMUNON's CEO Dr. Corinne Le Goff presented the company's advancements in DNA-mediated immunotherapy and vaccine platforms. She outlined IMUNON's progress in their TheraPlas and PlaCCine technologies, highlighting promising clinical results and a strong financial position. Representatives engaged with investors and partners during the convention, emphasizing IMUNON's commitment to developing transformative treatments for various diseases. The presentation underscored the potential of their lead program IMNN-001 in battling ovarian cancer.
Read more →IMNNIMUNON Presents PlaCCine Preclinical Data at the 2023 Viruses and Cells – Gordon Research Conference
IMUNON, Inc. presented promising preclinical data for its PlaCCine platform at the 2023 Viruses and Cells – Gordon Research Conference. The studies indicated that their COVID-19 vaccine exhibits persistent humoral immune responses that last over 14 months, outstripping those of existing mRNA vaccines. Additionally, the vaccine shows robust stability at refrigeration and room temperatures, making it feasible for deployment. IMUNON plans to file for an IND with the FDA as it progresses toward initiating Phase 1 studies in early 2024.
Read more →IMNN▼ -5.2%on this news
IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance
IMUNON, Inc. reported positive financial results for Q1 2023, highlighting a robust cash position that will support operations until 2025. The company provided updates on its clinical programs, particularly the IMNN-001 immunotherapy for ovarian cancer and the PLACCINE non-viral vaccine platform, which has shown promising results in preclinical studies. IMUNON announced new research collaborations aimed at advancing its vaccine formulations and revealed plans for upcoming clinical trials, underscoring a strong outlook for the company's pipeline. Overall, the firm projected multiple near-term milestones that could drive value for shareholders.
Read more →IMNNIMUNON to Hold First Quarter 2023 Financial Results and Business Update Conference Call on Thursday, May 11, 2023
IMUNON, Inc. is scheduled to hold a conference call on May 11, 2023, to discuss its financial results for the first quarter of 2023 and update on its clinical developments. The call will focus on IMNN-001, a DNA-based immunotherapy for advanced-stage ovarian cancer, currently in Phase 2 trials. Additionally, the company is studying its PLACCINE technology, a multivalent DNA-based plasmid platform, for potential superiority to existing mRNA vaccines. IMUNON's approaches aim to enhance treatment options for various diseases.
Read more →IMNN▲ +16%on this news
IMUNON Presents Poster at the American Association for Cancer Research Annual Meeting Demonstrating Preclinical Immune Response of IMNN-001
IMUNON, Inc. presented research on its DNA-based immunotherapy, IMNN-001, at the AACR Annual Meeting. The study focused on the immune response of IMNN-001 in a mouse model of advanced ovarian cancer, comparing different dosing regimens. Notably, the biweekly dosing regimen demonstrated efficacy comparable to weekly dosing while being superior to a three-week interval, supporting further investigation in human clinical studies. The findings could inform future combination studies with other treatments, enhancing the company’s clinical development strategy.
Read more →IMNNIMUNON Reports 2022 Financial Results and Provides Business Update Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J. (
IMUNON, Inc. reported its 2022 financial results and a business update, showcasing progress in its clinical programs, particularly the Phase 1/2 OVATION 2 Study with IMNN-001 for ovarian cancer. The company has demonstrated promising results from its PLACCINE technology in preclinical studies, positioning it as a potential next-generation vaccine platform. With a strong cash reserve of $38.9 million, IMUNON plans to continue advancing its immunotherapy and vaccine development efforts, including a future IND application for a seasonal COVID-19 booster. New collaborations aim to enhance the PLACCINE modality, indicating strategic growth for the company.
Read more →IMNNIMUNON to Hold Fourth Quarter 2022 Financial Results and Business Update Conference Call on Thursday, March 30, 2023
IMUNON, Inc. will hold a conference call on March 30, 2023, to discuss its fourth quarter and full year 2022 financial results, alongside updates on its clinical programs. The company is focusing on its lead candidate, IMNN-001, which is in Phase 2 trials for advanced ovarian cancer, and its PLACCINE platform, which is aiming to advance nucleic acid vaccines. The call will be accessible via toll-free numbers and will also be available for replay on their website.
Read more →IMNNIMUNON Presents PLACCINE Data at Vaccine Technology Summit 2023
IMUNON, Inc. presented data on its PLACCINE platform at the Vaccine Technology Summit 2023, showcasing significant preclinical results. The presentation highlighted PLACCINE's capability for broad spectrum immunity from a single DNA plasmid and its comparable efficacy to existing mRNA vaccines. The technology is distinguished by its long shelf-life and potential for rapid, scalable production. The company aims to develop PLACCINE as a superior alternative to current vaccines, indicating optimism about its future in the immunotherapy and vaccine landscape.
Read more →IMNNIMUNON Announces Abstract Accepted for Presentation at the American Association for Cancer Research Annual Meeting
IMUNON, Inc. announced that an abstract for its DNA-based immunotherapy, IMNN-001, has been accepted for presentation at the AACR Annual Meeting. The presentation will take place on April 18, 2023, showcasing efficacy results at different dose frequencies. IMNN-001, designed to treat advanced ovarian cancer, is currently in Phase 2 development, representing a significant advancement for the company. This presentation demonstrates IMUNON's commitment to innovating treatments that utilize the body's natural immune responses.
Read more →IMNNIMUNON CEO Issues Letter to Shareholders
IMUNON, Inc. announced a letter from CEO Dr. Corinne Le Goff, outlining the company's achievements in 2022 and setting ambitious goals for 2023. The company is focused on developing cutting-edge therapies in immuno-oncology and infectious diseases using their proprietary technologies. Notable progress includes advancements in a Phase 1/2 study for IMNN-001 in advanced ovarian cancer and promising results from their PLACCINE vaccine technology. IMUNON also aims to strategically partner with other organizations to further enhance its capabilities in DNA medicines.
Read more →IMNNIMUNON and Break Through Cancer Commence Enrollment in a Phase 1/2 Clinical Study of IMNN-001 in Combination with Avastin in Advanced Ovarian Cancer
IMUNON, Inc. has begun enrollment for a Phase 1/2 clinical trial assessing IMNN-001, an immunotherapy, in combination with Avastin for patients with advanced ovarian cancer. The study, funded in part by Break Through Cancer, aims to enroll 50 patients to evaluate its effectiveness against minimal residual disease. Initial data on surgical outcomes are expected within a year, with comprehensive progression-free survival data projected three years post-enrollment. This collaboration highlights the need for innovative treatment approaches in a significantly challenging cancer landscape.
Read more →IMNNIMUNON Receives $1.6 Million from Sale of its New Jersey Net Operating Losses
IMUNON, Inc. has secured $1.6 million through the sale of unused New Jersey net operating losses as part of a program to support biotech companies. This non-dilutive funding will strengthen the company's financial position and is expected to extend its operating runway until 2025. IMUNON plans to sell an additional $1.8 million in net operating losses later in 2023, highlighting the ongoing support from state programs for innovative businesses. The company's funding strategy is designed to support its clinical development programs and innovative therapeutic initiatives.
Read more →IMNNIMUNON Enters into Collaborative Research Agreement with The Wistar Institute’s Vaccine & Immunotherapy Center to Research IMUNON’s PLACCINE Vaccine Platform
IMUNON, Inc. has entered a collaborative research agreement with The Wistar Institute's Vaccine & Immunotherapy Center to develop new vaccine formulations using IMUNON's PLACCINE platform. This strategic partnership intends to advance the creation of vaccines targeting infectious diseases, bolstered by Wistar's renowned expertise in biomedical research. IMUNON's technology, focused on nucleic acid delivery systems, promises innovative solutions. The company is also pursuing other product developments, including its clinical program for advanced ovarian cancer.
Read more →IMNNIMUNON Reports Inducement Grants under NASDQ Listing Rule 5646(c)(4)
LAWRENCEVILLE, N.J., Dec. 14, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company’s Board of Directors appro
Read more →IMNNIMUNON Presentation at World Vaccine & Immunotherapy Congress Highlights PLACCINE Preclinical Proof of Concept and Key Competitive Advantages
LAWRENCEVILLE, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, announces that Khursheed Anwer, Ph.D., the company’s Executive Vice President and Chief Science Officer, presented today at the World Vaccine & Immunothe
Read more →IMNNIMUNON to Participate in the A.G.P./Alliance Global Partners Virtual Biotech Conference on November 30, 2022 – December 1, 2022
LAWRENCEVILLE, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff, President and Chief Executive Officer and Mr. Jeffrey Church, Executive Vice President and Chief Financial Offi
Read more →IMNNIMUNON Announces Strategic Investment in Transomic Technologies
Investment of $375,000 with Senior Convertible Notes and Warrants; Strengthens Development Capabilities for IMUNON’s PLACCINE DNA Vaccine Platform IMUNON’s Executive Chairman to join Transomic’s Board of Directors LAWRENCEVILLE, N.J., Nov. 17, 2022 (GLOBE NEWSWIRE) -- IMUNON, I
Read more →IMNNIMUNON, Inc. Third Quarter 2022 Conference Call Monday
Quarter 2022 Conference Call stand by. Good morning. My name is Marlise and I will be your operator today. At this time, I would like to welcome you to IMUNON's third quarter 2022 financial results conference call. All lines have been placed on mute to prevent any background no
Read more →IMNNIMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update Conference Call Today at 11:00 a.m. ET LAWRENCEVILLE, N.J. (
Reports Third Quarter 2022 Financial Results Provides Business Update Conference Call Today at 11:00 a.m. ET N.J. (November 14, 2022) - IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation
Read more →IMNNIMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNON’s PLACCINE Plasmid DNA with Acuitas’ Lipid Nanoparticle Delivery System
Successful combination of technologies will expand the opportunities for IMUNON’s DNA-based modality and broaden applications for the PLACCINE nucleic acid vaccine platform as an alternative to mRNA and protein vaccines LAWRENCEVILLE, N.J. and VANCOUVER, B.C., Nov. 10, 2022 (GLO
Read more →IMNNImunon to Hold Third Quarter 2022 Financial Results and Business Update Conference Call on Monday, November 14, 2022
LAWRENCEVILLE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on DNA-mediated immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monda
Read more →IMNNImunon Reports Partial Results from Ongoing Non-human Primate Study
Supports PLACCINE Platform as a Viable Alternative to mRNA Vaccines LAWRENCEVILLE, N.J., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, reports that partial results from an ongoing non-human primate study designed to exa
Read more →IMNNImunon Appoints James E. Dentzer to its Board of Directors CEO of Curis brings extensive biopharmaceutical financial experience to the Board LAWRENCEVILLE, N.J. (
Appoints James E. Dentzer to its Board of Directors of Curis brings extensive biopharmaceutical financial experience to the Board N.J. (October 3, 2022) - Imunon, Inc. (Nasdaq: IMNN), a clinical-stage drug development company, announces the appointment of James E. Dentzer to i
Read more →IMNNIMUNON to Present at Chardan’s 6th Annual Genetic Medicines Conference
LAWRENCEVILLE, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1x1 meetings at the
Read more →IMNNCelsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins
Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT N.J. (August 15, 2022) - Celsion Corporation
Read more →IMNNCelsion Appoints Dr. Corinne Le Goff as President and Chief Executive Officer Michael H. Tardugno appointed Executive Chairman of the Board LAWRENCEVILLE, N.J.
Appoints Dr. Corinne Le Goff as President and Chief Executive Officer H. Tardugno appointed Executive Chairman of the Board N.J., July 19, 2022 - Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today
Read more →IMNNCelsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins T
Celsion Corporation Reports First Quarter 2022 Financial Results and Provides Business Update DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J. (May 16, 202
Read more →IMNNCELSION CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET
CORPORATION ANNOUNCES $7.0 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES NJ, April 6, 2022 - Celsion Corporation (NASDAQ: CLSN) ("Celsion" or the "Company"), today announced it has entered into definitive agreements with institutional investors for
Read more →IMNNCelsion Corporation Reports 2021 Financial Results and Provides Business Update Focus on Cancer Immunotherapy and Next-Generation Vaccines and a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. Eastern Tim
Corporation Reports 2021 Financial Results and Provides Business Update on Cancer Immunotherapy and Next-Generation Vaccines and a Strong Balance Sheet Call Begins Today at 11:00 a.m. Eastern Time N.J. (March 31, 2022) - Celsion Corporation (NASDAQ: CLSN), a clinical-stage dr
Read more →IMNNCelsion Corporation Announces Stock Consolidation LAWRENCEVILLE, N.J.
Corporation Announces Stock Consolidation N.J., February 28, 2022 - Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that, as previously authorized by its shareholders, the Company is i
Read more →IMNNCelsion Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock LAWRENCEVILLE, N.J.
Corporation Announces Pricing of $30 Million Registered Direct Offerings of Convertible Redeemable Preferred Stock N.J., January 13, 2022 - Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines,
Read more →IMNNCelsion Corporation Reports Third Quarter 2021 Financial Results and Provides Business Update Balance Sheet Supports Focus on Immuno-Oncology and Next-Generation Vaccine Initiative Conference Call Begins Today at 11:00 a
Corporation Reports Third Quarter 2021 Financial Results and Provides Business Update Sheet Supports Focus on Immuno-Oncology and Next-Generation Vaccine Initiative Call Begins Today at 11:00 a.m. Eastern Time N.J. (November 15, 2021) - Celsion Corporation (NASDAQ: CLSN), a cl
Read more →IMNNCelsion Corporation Reports Second Quarter 2021 Financial Results and Provides Business Update Strong Balance Sheet Supports Focus in Immuno-Oncology and on Next-Generation Vaccine Initiative Conference Call Begins Today
Corporation Reports Second Quarter 2021 Financial Results and Provides Business Update Balance Sheet Supports Focus in Immuno-Oncology and on Next-Generation Vaccine Initiative Call Begins Today at 11:00 a.m. Eastern Time N.J. (August 12, 2021) - Celsion Corporation (NASDAQ: C
Read more →IMNNCelsion Corporation Enters into $10 Million Strategic Loan Facility with Silicon Valley Bank Improvement to the Balance Sheet Leverages Strong Equity Structure Retires Debt and Gains Five Months of Operating Runway at Ve
Corporation Enters into $10 Million Strategic Loan Facility with Silicon Valley Bank to the Balance Sheet Leverages Strong Equity Structure Debt and Gains Five Months of Operating Runway at Very Low Cost of Capital N.J. (June 21, 2021) - Celsion Corporation (NASDAQ: CLSN), a c
Read more →IMNNCELSION CORPORATION ANNOUNCES ADJOURNMENT OF ANNUAL MEETING A Quorum Has Been Achieved to Reconvene Annual Meeting on Thursday
CORPORATION ANNOUNCES ADJOURNMENT OF ANNUAL MEETING Quorum Has Been Achieved to Reconvene Annual Meeting on Thursday June 10, 2021 Remain Open, Shareholders are Urged to Vote N.J., June 7 2021 - Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused o
Read more →IMNNCelsion Corporation Appoints Dr. Stacy R. Lindborg to its Board of Directors 25-year pharmaceutical industry executive brings broad drug development perspective Replaces Alberto Martinez, MD LAWRENCEVILLE, N.J. (
Corporation Appoints Dr. Stacy R. Lindborg to its Board of Directors pharmaceutical industry executive brings broad drug development perspective Alberto Martinez, MD N.J. (June 8, 2021) - Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunot
Read more →IMNNCELSION CORPORATION ANNOUNCES ADJOURNMENT OF ANNUAL MEETING 49% of Shares Voted, Quorum Not Established To Hold Annual Meeting Polls Remain Open Stockholders Holding Unvoted Proxies Are Strongly Encouraged to Vote Their
CORPORATION ANNOUNCES ADJOURNMENT OF ANNUAL MEETING of Shares Voted, Quorum Not Established To Hold Annual Meeting Holding Unvoted Proxies Are Strongly Encouraged to Vote Their Shares N.J., June 4, 2021 - Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company
Read more →IMNNCelsion Corporation Reports First Quarter 2021 Financial Results and Provides Business Update Focus on Immuno-Oncology and Next-Generation Vaccines is Supported with a Strong Balance Sheet Conference Call Begins at 10:00
Corporation Reports First Quarter 2021 Financial Results and Provides Business Update on Immuno-Oncology and Vaccines is Supported with a Strong Balance Sheet Call Begins at 10:00 a.m. Eastern Time Today N.J. (May 14, 2021) - Celsion Corporation (NASDAQ: CLSN), a clinical-sta
Read more →IMNNCELSION CORPORATION ANNOUNCES $15 MILLION REGISTERED DIRECT OFFERING LAWRENCEVILLE, NJ /
CORPORATION ANNOUNCES $15 MILLION REGISTERED DIRECT OFFERING NJ / March 31, 2021 / Celsion Corporation (NASDAQ: CLSN) ("Celsion" or the "Company"), today announced it has entered into definitive agreements with institutional investors for the purchase and sale of 11,538,462 sha
Read more →IMNNCelsion Corporation Reports 2020 Financial Results and Provides Business Update Entered 2021 with a Focus on Cancer Immunotherapy and Next-Generation Infectious Vaccines and a Strong Balance Sheet Conference Call Begins
Corporation Reports 2020 Financial Results and Provides Business Update 2021 with a Focus on Cancer Immunotherapy and Infectious Vaccines and a Strong Balance Sheet Call Begins at 11:00 a.m. Eastern Time Today N.J. (March 19, 2021) - Celsion Corporation (NASDAQ: CLSN), a clin
Read more →IMNNCelsion Corporation Issues Letter to Stockholders Discusses Broad-based DNA Vaccine Initiative, OVATION 2 Study, and Phase III OPTIMA Study Conclusions LAWRENCEVILLE, N.J. (
Corporation Issues Letter to Stockholders Broad-based DNA Vaccine Initiative, OVATION 2 Study, Phase III OPTIMA Study Conclusions N.J. (February 11, 2021) - Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that Michael H. Tardugno, the
Read more →IMNNCELSION CORPORATION ANNOUNCES $35 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES LAWRENCEVILLE, NJ /
CORPORATION ANNOUNCES $35 MILLION REGISTERED DIRECT OFFERING PRICED AT-THE-MARKET UNDER NASDAQ RULES NJ / January 22, 2021 / Celsion Corporation (NASDAQ: CLSN) ("Celsion" or the "Company"), today announced it has entered into definitive agreements with institutional investors f
Read more →IMNNCelsion Corporation Reports Third Quarter 2020 Financial Results and Provides Business Update Initiates Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer Continues Following Patients for Overall Survival in Ph
Corporation Reports Third Quarter 2020 Financial Results and Provides Business Update Phase II OVATION 2 Study of GEN-1 in Advanced Ovarian Cancer Following Patients for Overall Survival in Phase III OPTIMA Study Call Begins Today at 11:00 a.m. Eastern Time N.J. (November 16,
Read more →IMNNCelsion Announces Common Stock Purchase Agreement with Lincoln Park Capital and Provides Updates on OVATION 2 Study Agreement Includes 1 Million Shares Purchased at 28% Market Premium LAWRENCEVILLE, N.J. (
Announces Common Stock Purchase Agreement with Lincoln Park Capital and Provides Updates on OVATION 2 Study Includes 1 Million Shares Purchased at 28% Market Premium N.J. (September 8, 2020) - Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today provi
Read more →IMNNCelsion Corporation Reports Second Quarter 2020 Financial Results and Provides Business Update Initiates Promising Phase II Study of GEN-1 in Advanced Ovarian Cancer Will Continue Following Patients in Phase III OPTIMA S
Corporation Reports Second Quarter 2020 Financial Results and Provides Business Update Promising Phase II Study of GEN-1 in Advanced Ovarian Cancer Continue Following Patients in Phase III OPTIMA Study for Overall Survival; Call Begins Today at 11:00 a.m. Eastern Time N.J. (A
Read more →IMNNWILLIAM J. O'CONNOR , derivatively on behalf of CELSION CORPORATION and individually and on behalf of himself and all other similarly situated shareholders of CELSION CORPORATION, Plaintiff, v. Donald P. Braun, Augustine
TO SHAREHOLDERS OF CELSION CORPORATION April 24, 2020, Celsion Corporation ("Celsion" or the "Company") entered into a Settlement Agreement and Release (the "Agreement") in the above-captioned shareholder Action, pending in the Superior Court of New Jersey, Mercer Count Chance
Read more →IMNNCelsion Corporation Receives Recommendation from Independent Data Monitoring Committee to Consider Stopping the Phase III OPTIMA Study Recommendation Based on DMC's Finding Following the Second Pre-Planned Interim Analys
Corporation Receives Recommendation from Independent Data Monitoring Committee to Consider Stopping the Phase III OPTIMA Study Based on DMC's Finding Following the Second Pre-Planned Interim Analysis that the OPTIMA Study is Unlikely to Meet its Primary Efficacy Endpoint of Ove
Read more →IMNNCelsion Corporation Announces Pricing of $10 Million Underwritten Offering of Common Stock Lawrenceville, NJ
Corporation Announces Pricing of $10 Million Underwritten Offering of Common Stock NJ, June 22, 2020 - Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced the entry into an underwriting agreement relating to the sale of 2,666,667 shares of
Read more →IMNNCelsion Corporation Reports First Quarter 2020 Financial Results and Provides Business Update Phase III OPTIMA Study on Track for Interim Data Analysis in July Conference Call Begins Today at 11:00 a.m. Eastern Time LAWR
Corporation Reports First Quarter 2020 Financial Results and Provides Business Update III OPTIMA Study on Track for Interim Data Analysis in July Call Begins Today at 11:00 a.m. Eastern Time N.J. (May 15, 2020) - Celsion Corporation (NASDAQ: CLSN), an oncology drug development
Read more →IMNNCelsion Receives $2.5 Million in Non-Dilutive Funding from the Sale of its New Jersey State Net Operating Losses and Grant Funding Under the Paycheck Protection Program Added Capital Strengthens Balance Sheet, Assures Ca
Receives $2.5 Million in Non-Dilutive Funding from the Sale of its New Jersey State Net Operating Losses and Grant Funding Under the Paycheck Protection Program Capital Strengthens Balance Sheet, Assures Cash Through Major Phase III OPTIMA Study Data Readout Events of an Addit
Read more →IMNNCelsion Corporation Reports 2019 Financial Results and Provides Business Update Enters 2020 with a Strong Balance Sheet and an Advancing Clinical Pipeline Conference Call Begins at 11:00 a.m. Eastern Time on Thursday
Corporation Reports 2019 Financial Results and Provides Business Update 2020 with a Strong Balance Sheet and an Advancing Clinical Pipeline Call Begins at 11:00 a.m. Eastern Time on Thursday March 26, 2020 N.J. (March 25, 2019) - Celsion Corporation (NASDAQ: CLSN), an oncology
Read more →IMNNCelsion Corporation Prices $4.8 Million Registered Direct Offering LAWRENCEVILLE, NJ /
Corporation Prices $4.8 Million Registered Direct Offering NJ / February 28, 2020 / Celsion Corporation (NASDAQ: CLSN) ("Celsion" or the "Company"), today announced it has entered into securities purchase agreements with institutional investors for the purchase and sale of 4,57
Read more →IMNNCelsion Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update Independent Data Monitoring Committee (iDMC) Unanimously Recommends Continuation of Phase III OPTIMA Study at First Pre-Planne
Corporation Reports Third Quarter 2019 Financial Results and Provides Business Update Independent Data Monitoring Committee (iDMC) Unanimously Recommends Continuation of Phase III OPTIMA Study at First Pre-Planned Efficacy Analysis Independent Data Safety Monitoring Board (D
Read more →IMNNCelsion Corporation Reports Second Quarter 2019 Financial Results and Provides Business Update First Pre-Planned Efficacy Analysis of the Phase III OPTIMA Study Planned for Mid-October Strong Balance Sheet Plus the Non-D
Corporation Reports Second Quarter 2019 Financial Results and Provides Business Update Pre-Planned Efficacy Analysis of the Phase III OPTIMA Study Planned for Mid-October Balance Sheet Plus the Non-Dilutive Sale of $4 Million of New Jersey State Net Operating Losses Will Fund O
Read more →IMNNCelsion Corporation Reports First Quarter 2019 Financial Results and Provides Business Update Company to Hold Conference Call on Wednesday
Corporation Reports First Quarter 2019 Financial Results and Provides Business Update to Hold Conference Call on Wednesday, May 15, 2019 at 11:00 a.m. EDT N.J., May 15, 2019 - Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced financial r
Read more →IMNNCelsion Corporation Reports 2018 Financial Results Celsion Enters 2019 with a Strong Balance Sheet, Clean Capitalization Structure and an Advancing Clinical Pipeline Company to Hold Conference Call on Friday
Corporation Reports 2018 Financial Results Enters 2019 with a Strong Balance Sheet, Clean Capitalization Structure and an Advancing Clinical Pipeline to Hold Conference Call on Friday, March 29, 2019 at 11:00 a.m. EDT N.J., March 29, 2019 - Celsion Corporation (NASDAQ: CLSN),
Read more →IMNNCelsion Corporation Reports Third Quarter 2018 Financial Results and Provides Business Update ThermoDox Phase III OPTIMA Study Fully Enrolled in August; First Pre-Planned Efficacy Analysis Expected in Mid-2019 GEN-1 Phas
Corporation Reports Third Quarter 2018 Financial Results and Provides Business Update Phase III OPTIMA Study Fully Enrolled in August; First Pre-Planned Efficacy Analysis Expected in Mid-2019 Phase I/II OVATION 2 Study Enrolling Patients; First Look at I Data Expected in Firs
Read more →IMNNCelsion Corporation Reports Second Quarter 2018 Financial Results and Provides Business Update Strong Balance Sheet With Cash Sufficient to Fund Operations Into the First Half of 2020 Quarterly and Year-to-Date Cash Expe
Corporation Reports Second Quarter 2018 Financial Results Provides Business Update Balance Sheet With Cash Sufficient to Fund Operations Into the First Half of 2020 and Year-to-Date Cash Expenses Consistent With Prior Guidance to Hold Conference Call on Tuesday, August 14, 20
Read more →IMNNCelsion Corporation Reports First Quarter 2018 Financial Results and Provides Business Update Significant Progress in Phase III Liver Cancer and Phase I/II Ovarian Cancer Studies Supported with Solid Fundamentals and a S
Corporation Reports First Quarter 2018 Financial Results Provides Business Update Progress in Phase III Liver Cancer and Phase I/II Ovarian Cancer Studies with Solid Fundamentals and a Strong Balance Sheet to Hold Conference Call on Friday, May 11, 2018 at 11:00 a.m. EDT N.J
Read more →IMNNCelsion Corporation Reports Second Quarter 2017 Financial Results and Provides Business Update Company to Hold Conference Call on Tuesday
Celsion Corporation Reports Second Quarter 2017 Financial Results and Provides Business Update Company to Hold Conference Call on Tuesday, August 15, 2017 at 11:00 a.m. ET LAWRENCEVILLE, N.J., August 15, 2017 -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development c
Read more →IMNNCelsion Corporation Announces $5 Million Registered Direct Offering LAWRENCEVILLE, N.J.
Celsion Corporation Announces $5 Million Registered Direct Offering LAWRENCEVILLE, N.J. - July 6, 2017 - Celsion Corporation (the "Company") (NASDAQ: CLSN) today announced that it has entered into definitive agreements with several institutional investors to purchase an aggregat
Read more →IMNNCelsion Corporation Announces Cancellation of Registered Direct Offering LAWRENCEVILLE, N.J.
Celsion Corporation Announces Cancellation of Registered Direct Offering LAWRENCEVILLE, N.J. - June 22, 2017 - Celsion Corporation (the "Company") (NASDAQ: CLSN) today announced that it has cancelled the registered direct offering of common stock announced Monday, June 19, 2017.
Read more →IMNNCelsion Corporation Announces $5.4 Million Registered Direct Offering LAWRENCEVILLE, N.J.
Celsion Corporation Announces $5.4 Million Registered Direct Offering LAWRENCEVILLE, N.J. - June 19, 2017 - Celsion Corporation (the "Company") (NASDAQ: CLSN) today announced that it has entered into definitive agreements with several institutional investors to purchase an aggre
Read more →IMNNCelsion Corporation Regains Compliance with NASDAQ Listing Requirements LAWRENCEVILLE, N.J.
Celsion Corporation Regains Compliance with NASDAQ Listing Requirements LAWRENCEVILLE, N.J., June 14, 2017 -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that it received notice from The NASDAQ Stock Market LLC (NASDAQ) on June 13, 2
Read more →IMNNCelsion Corporation Announces Stock Consolidation Strategic Move to Attract a Broader Range of Investors, t o Ensu re a Strong Balance Sheet, and t o Enable the Expansion of the Company's Product Pipeline LAWRENCEVILLE,
Celsion Corporation Announces Stock Consolidation Strategic Move to Attract a Broader Range of Investors, to Ensure a Strong Balance Sheet, and to Enable the Expansion of the Company's Product Pipeline LAWRENCEVILLE, N.J. -- May 26, 2017 -- Celsion Corporation (NASDAQ: CLSN),
Read more →IMNNCelsion Corporation Reports First Quarter 2017 Financial Results and Provides Business Update Company to Hold Confer ence Call on Friday
Celsion Corporation Reports First Quarter 2017 Financial Results and Provides Business Update Company to Hold Conference Call on Friday, May 12, 2017 at 11:00 a.m. ET LAWRENCEVILLE, N.J., May 12, 2017 -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company,
Read more →IMNNCelsion Corporation Reports Year End 201 6 Financial Results and Provides Business Update Company to Hold Confer ence Call on Thursday
Celsion Corporation Reports Year End 2016 Financial Results and Provides Business Update Company to Hold Conference Call on Thursday, March 16, 2017 at 11:00 a.m. ET LAWRENCEVILLE, N.J., March 16, 2017 -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company,
Read more →IMNNCelsion Corporation Announces $5.0 Million Public Offering LAWRENCEVILLE, N.J.
Celsion Corporation Announces $5.0 Million Public Offering LAWRENCEVILLE, N.J. - February 15, 2017 - Celsion Corporation (the "Company") (NASDAQ: CLSN) today announced the pricing of a public offering with expected total gross proceeds of approximately $5.0 million. The offerin
Read more →IMNNCelsion Corporation Announces $1.8 Million Registered Direct Offering LAWRENCEVILLE, N.J.
Celsion Corporation Announces $1.8 Million Registered Direct Offering LAWRENCEVILLE, N.J. - December 20, 2016 - Celsion Corporation (the "Company") (NASDAQ: CLSN) today announced that it has entered into a definitive agreement with several institutional investors to purchase an
Read more →IMNNCelsion Corporation Reports Third Quarter 2016 Financial Results and Provides Business Update Meaningful Progress with the ThermoDox OPTIMA Study and GEN-1 Immunotherapy Program , Including Highly Encouraging Data from P
Celsion Corporation Reports Third Quarter 2016 Financial Results and Provides Business Update Meaningful Progress with the ThermoDox OPTIMA Study and GEN-1 Immunotherapy Program, Including Highly Encouraging Data from Primary Liver and Ovarian Cancer Studies Company to Hold Con
Read more →IMNNCelsion Corporation Reports Second Quarter 2016 Financial Results and Provides Business Update Significant Progress in Immuno-oncology and Chemotherapy Clinical Research Complimented with a 20% Reduction in Operating Exp
Celsion Corporation Reports Second Quarter 2016 Financial Results and Provides Business Update Significant Progress in Immuno-oncology and Chemotherapy Clinical Research Complimented with a 20% Reduction in Operating Expenses Company to Hold Conference Call on Monday, August 15
Read more →IMNNCelsion Corporation Announces $6 Million Registered Direct Offering LAWRENCEVILLE, N.J.
Celsion Corporation Announces $6 Million Registered Direct Offering LAWRENCEVILLE, N.J. - June 13, 2016 - Celsion Corporation (the "Company") (NASDAQ: CLSN) today announced that it has entered into a definitive agreement with a single healthcare dedicated institutional investor
Read more →IMNNCelsion Corporation Reports First Quarter 2016 Financial Results and Provides Business Update Company to Hold Conference Call on Monday
Celsion Corporation Reports First Quarter 2016 Financial Results and Provides Business Update Company to Hold Conference Call on Monday, May 16, 2016 at 11:00 a.m. EDT LAWRENCEVILLE, N.J., May 16, 2016 -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company
Read more →IMNNCelsion Corporation Reports Year End 2015 Financial Results and Provides Business Update Company to Hold Conference Call on Wednesday
Celsion Corporation Reports Year End 2015 Financial Results and Provides Business Update Company to Hold Conference Call on Wednesday, March 30, 2016 at 11:00 a.m. EDT LAWRENCEVILLE, N.J., March 30, 2016 -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development compa
Read more →IMNNCelsion Announces Appointment of Two New Members to Its Board of Directors LAWRENCEVILLE, N.J.
Celsion Announces Appointment of Two New Members to Its Board of Directors LAWRENCEVILLE, N.J. - December 17, 2015 - Celsion Corporation (NASDAQ: CLSN), a fully-integrated oncology company focused on the development of a portfolio of innovative cancer treatments, including direc
Read more →IMNNCelsion Corporation Reports Third Quarter 2015 Financial Results and Provides Business Update Company to Hold Conference Call on Thursday , November 5 , 2015 at 11:00 a.m. E S T LAWRENCEVILLE, NJ
Celsion Corporation Reports Third Quarter 2015 Financial Results and Provides Business Update Company to Hold Conference Call on Thursday, November 5, 2015 at 11:00 a.m. EST LAWRENCEVILLE, NJ - November 5, 2015 - Celsion Corporation (NASDAQ: CLSN), an oncology drug development
Read more →IMNNCelsion Corporation Reports Second Quarter 2015 Financial Results and Provides Business Update ThermoDox and GEN-1 Advancing Toward Key Trials Later this Year Company to Hold Conference Call on Monday , August 10 , 2015
Celsion Corporation Reports Second Quarter 2015 Financial Results and Provides Business Update ThermoDox and GEN-1 Advancing Toward Key Trials Later this Year Company to Hold Conference Call on Monday, August 10, 2015 at 11:00 a.m. EDT LAWRENCEVILLE, NJ - August 10, 2015 - Cel
Read more →IMNNCelsion Corporation Announces $8 Million At-The-Market Registered Direct Offering LAWRENCEVILLE, N.J.
Celsion Corporation Announces $8 Million At-The-Market Registered Direct Offering LAWRENCEVILLE, N.J. - May 28, 2015 - Celsion Corporation (the "Company") (NASDAQ: CLSN) today announced that it has received commitments from two institutional healthcare investors to purchase an a
Read more →IMNNCelsion Corporation Reports First Quarter 2015 Financial Results and Provides Business Update Recruitment for the OPTIMA Study is Well Underway in U.S., Europe and Asia Pacific On Track to Launch Euro-DIGNITY Trial and P
Celsion Corporation Reports First Quarter 2015 Financial Results and Provides Business Update Recruitment for the OPTIMA Study is Well Underway in U.S., Europe and Asia Pacific On Track to Launch Euro-DIGNITY Trial and Phase Ib GEN-1 First-Line Trial Mid-Year Company to Hold C
Read more →IMNNCelsion Corporation Reports Year End 2014 Financial Results and Provides Business Update Clinical Development Pathway Established for GEN-1 in Ovarian and Brain Cancer; Phase III OPTIMA Trial Actively Recruiting Patients
Celsion Corporation Reports Year End 2014 Financial Results and Provides Business Update Clinical Development Pathway Established for GEN-1 in Ovarian and Brain Cancer; Phase III OPTIMA Trial Actively Recruiting Patients in U.S., Europe and Asia Pacific; On Track to Launch Ph
Read more →IMNNCelsion Corporation and myTomorrows Partner to Introduce ThermoDox Early Access Program in Europe for Patients with Recurrent Chest Wall Breast Cancer Lawrenceville, NJ
Celsion Corporation and myTomorrows Partner to Introduce ThermoDox Early Access Program in Europe for Patients with Recurrent Chest Wall Breast Cancer Lawrenceville, NJ -- January 20, 2015 /PR Newswire/ -- Celsion Corporation (NASDAQ:CLSN), a fully-integrated oncology company fo
Read more →IMNNCelsion Corporation Reports Third Quarter 2014 Financial Results Company Completes Acquisition and Integration of EGEN, Inc. ; Enrollment Underway in Phase III OPTIMA Study ; Initiates Phase II Euro-DIGINTY Study for RCW
Celsion Corporation Reports Third Quarter 2014 Financial Results Company Completes Acquisition and Integration of EGEN, Inc.; Enrollment Underway in Phase III OPTIMA Study; Initiates Phase II Euro-DIGINTY Study for RCW Breast Cancer; Establishes Clinical Study Plans for EGEN-
Read more →IMNNCelsion Announces Appointment of Michael H. Tardugno to Executive Chairman of the Board of Directors LAWRENCEVILLE, N.J.
Celsion Announces Appointment of Michael H. Tardugno to Executive Chairman of the Board of Directors LAWRENCEVILLE, N.J. - October 7, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced that the Board of Directors has appointed Michael H. Tardugno, the Company's Pr
Read more →IMNNCelsion Corporation Reports Second Quarter 2014 Financial Results Company Completes Acquisition of EGEN, Inc. Company to Hold Conference Call Today at 11:00 a.m.
Celsion Corporation Reports Second Quarter 2014 Financial Results Company Completes Acquisition of EGEN, Inc. Company to Hold Conference Call Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J. - August 7, 2014 - Celsion Corporation (NASDAQ: CLSN), an oncology drug development company
Read more →IMNNCelsion Corporation Completes Acquisition of EGEN, Inc. Transaction Forms Fully-Integrated Oncology Discovery and Development Company Creates Multi-Phase Clinical Pipeline with Celsion's Phase III Product Candidate Therm
Celsion Corporation Completes Acquisition of EGEN, Inc. Lawrenceville, NJ -- June 20, 2014 /PR Newswire/ -- Celsion Corporation (Celsion) (NASDAQ: CLSN), an oncology drug development company, today announced the completion of the acquisition by Celsion of substantially all of th
Read more →IMNNCelsion Corporation to Acquire EGEN, Inc. Transaction Forms Fully-Integrated Oncology Discovery and Development Company Creates Multi-Phase Clinical Pipeline with Celsion's Phase III Product Candidate ThermoDox and EGEN'
Celsion Corporation to Acquire EGEN, Inc. Lawrenceville, NJ and Huntsville, AL -- June 10, 2014 /PR Newswire/ -- Celsion Corporation (Celsion) (NASDAQ:CLSN), an oncology drug development company, and EGEN, Inc. (EGEN), a privately-held biopharmaceutical company focused on the de
Read more →IMNNCelsion Corporation Reports First Quarter 2014 Financial Results and Provides Business Update Company on Track to Launch Phase III OPTIMA Study in Second Quarter Company to Hold Conference Call on Thursday
Celsion Corporation Reports First Quarter 2014 Financial Results and Provides Business Update Company on Track to Launch Phase III OPTIMA Study in Second Quarter Company to Hold Conference Call on Thursday, May 8, 2014 at 11:00 a.m. EST LAWRENCEVILLE, N.J. - May 8, 2014 - Cels
Read more →IMNNCelsion Corporation Reports Year End 2013 Financial Results and Provides Business Update Overall Survival Data from the HEAT Study Supports Continued Clinical Development of ThermoDox in Primary Liver Cancer Well Positio
Celsion Corporation Reports Year End 2013 Financial Results and Provides Business Update Overall Survival Data from the HEAT Study Supports Continued Clinical Development of ThermoDox in Primary Liver Cancer Well Positioned, Financing Ensures a Strong Balance Sheet Company to
Read more →IMNNCelsion Corporation Announces $15 Million At-The-Market Registered Direct Offering LAWRENCEVILLE, N.J.
Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering LAWRENCEVILLE, N.J. -January 15, 2014 - Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has received commitments from institutional investors to purchase an aggregate of
Read more →IMNNCelsion Corporation Reports Third Quarter 2013 Financial Results and Provides Business Update Strong Balance Sheet Supports Ongoing ThermoDox Development Program Company to Hold Conference Call on Tuesday
Celsion Corporation Reports Third Quarter 2013 Financial Results and Provides Business Update Strong Balance Sheet Supports Ongoing ThermoDox Development Program Company to Hold Conference Call on Tuesday, November 12, 2013 at 11:00 a.m. EST LAWRENCEVILLE, N.J. - November 12,
Read more →IMNNCelsion Corporation Announces Stock Consolidation Strategic Move to Attract a Broader Range of Investors, To Ensure a Strong Balance Sheet, and To Enable the Expansion of the Company's Product Pipeline LAWRENCEVILLE, NJ
Celsion Corporation Announces Stock Consolidation Strategic Move to Attract a Broader Range of Investors, To Ensure a Strong Balance Sheet, and To Enable the Expansion of the Company's Product Pipeline LAWRENCEVILLE, NJ - October 28, 2013 - Celsion Corporation (NASDAQ: CLSN),
Read more →IMNNCelsion Corporation Reports Second Quarter 2013 Financial Results and Provides HEAT Study Update Analysis of Overall Survival Data in the HEAT Study Continues to Show ThermoDox Improves Survival Benefit when RFA Heating
Celsion Corporation Reports Second Quarter 2013 Financial Results and Provides HEAT Study Update Analysis of Overall Survival Data in the HEAT Study Continues to Show ThermoDox Improves Survival Benefit when RFA Heating is Optimized Company to Hold Conference Call on Thursday
Read more →IMNNCelsion Announces Jeffrey W. Church Reappointed to CFO Company Completes Previously Announced Restructuring and Cash Conservation Program LAWRENCEVILLE, N.J.
Celsion Announces Jeffrey W. Church Reappointed to CFO Company Completes Previously Announced Restructuring and Cash Conservation Program LAWRENCEVILLE, N.J., July 2, 2013 - Celsion Corporation (Nasdaq: CLSN) announced today that Jeffrey W. Church, Senior Vice President, will r
Read more →IMNNCelsion Corporation Announces $9.83 Million Registered Direct Offering LAWRENCEVILLE, N.J.
Celsion Corporation Announces $9.83 Million Registered Direct Offering LAWRENCEVILLE, N.J. - May 31, 2013 - Celsion Corporation (NASDAQ:CLSN) (the "Company") today announced that it has received commitments from institutional investors to purchase an aggregate of approximately $
Read more →IMNNCelsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update Company to Hold Conference Call on Thursday
Celsion Corporation Reports First Quarter 2013 Financial Results and Provides Business Update Company to Hold Conference Call on Thursday, May 9, 2013 at 11:00 a.m. ET LAWRENCEVILLE, NJ May 9, 2013 Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today
Read more →IMNNCelsion Corporation Reports Year End 2012 Financial Results and Provides Business Update Data from the HEAT Study Undergoing Rigorous Analysis; Recent Financing Ensures a Strong Balance Sheet Company to Hold Conference C
Celsion Corporation Reports Year End 2012 Financial Results and Provides Business Update Data from the HEAT Study Undergoing Rigorous Analysis; Recent Financing Ensures a Strong Balance Sheet Company to Hold Conference Call on Monday, March 18, 2013 at 11:00 a.m. ET LAWRENCE
Read more →IMNNCelsion Corporation Announces $15 Million Registered Direct Offering LAWRENCEVILLE, N.J.
Celsion Corporation Announces $15 Million Registered Direct Offering LAWRENCEVILLE, N.J. February 22, 2013 Celsion Corporation (the Company ) (NASDAQ:CLSN) today announced that it has received commitments from institutional investors to purchase an aggregate of $15 million of th
Read more →IMNNCelsion Corporation Provides an Update Regarding ThermoDox Agreements with Zhejiang HISUN Pharmaceutical Company for China Exclusive Option Agreement Will Be Allowed To Expire While Celsion Conducts Sub-Group Analysis of
Celsion Corporation Provides an Update Regarding ThermoDox Agreements with Zhejiang HISUN Pharmaceutical Company for China Exclusive Option Agreement Will Be Allowed To Expire While Celsion Conducts Sub-Group Analysis of Chinese Patient Cohort in Phase III HEAT Study Companies
Read more →IMNNCelsion Announces Results of Phase III HEAT Study of ThermoDox in Primary Liver Cancer Company to Host Conference Call at 8:00 AM EST Today LAWRENCEVILLE, NJ
Celsion Announces Results of Phase III HEAT Study of ThermoDox in Primary Liver Cancer Company to Host Conference Call at 8:00 AM EST Today LAWRENCEVILLE, NJ January 31, 2013 Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that T
Read more →IMNNCelsion Corporation and Zhejiang Hisun Pharmaceutical Company Enter Into Technology Development Agreement for ThermoDox for the Greater China Territory Companies Also Anticipate 60-Day Exclusive Option Period for Commerc
Celsion Corporation and Zhejiang Hisun Pharmaceutical Company Enter Into Technology Development Agreement for ThermoDox for the Greater China Territory Companies Also Anticipate 60-Day Exclusive Option Period for Commercial License for ThermoDox for China Market LAWRENCEVILLE
Read more →IMNNCelsion Corporation Selected Balance Sheet Information (in thousands)
Celsion Corporation Reports Third Quarter 2012 Financial Results and Business Update Company to Hold Conference Call on Monday, November 12, 2012 at 11:00 a.m. ET LAWRENCEVILLE, NJ - (Marketwire) - November 12, 2012 - Celsion Corporation (NASDAQ: CLSN), a leading oncology drug
Read more →IMNNCelsion Corporation Reports Second Quarter 2012 Financial Results and Business Update Company to Hold Conference Call on Tuesday
Celsion Corporation Reports Second Quarter 2012 Financial Results and Business Update Company to Hold Conference Call on Tuesday, August 14, 2012 at 11:00 a.m. ET LAWRENCEVILLE, N.J. - August 14, 2012 - Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development com
Read more →IMNNCelsion Reports First Quarter 2012 Financial Results Company to Hold Conference Call on Tuesday, May 15 th at 11:00 a.m.
Celsion Reports First Quarter 2012 Financial Results Company to Hold Conference Call on Tuesday, May 15th at 11:00 a.m. ET LAWRENCEVILLE, NJ - May 15, 2012 - Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced financial results for t
Read more →IMNNCelsion Reports Year End 2011 Financial Results and Provides Business Update Company to Hold Conference Call Today
Celsion Reports Year End 2011 Financial Results and Provides Business Update Company to Hold Conference Call Today, March 15, 2012 at 11:00 a.m. ET Lawrenceville, NJ - (MARKET WIRE) - March 15, 2012 - Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development compan
Read more →IMNNThe Investor Presentation of Celsion Corporation is contained in the corresponding .PDF File.
The Investor Presentation of Celsion Corporation is contained in the corresponding .PDF File.
Read more →IMNNCelsion Corporation to Raise $15 Million in Private Placement Investment by Leading Life Science Institutional Investors LAWRENCEVILLE, NJ
Celsion Corporation to Raise $15 Million in Private Placement Investment by Leading Life Science Institutional Investors LAWRENCEVILLE, NJ - December 1, 2011 - Celsion Corporation (NASDAQ:CLSN) today announced that it has received commitments from investors, including leading l
Read more →IMNNCelsion Announces Unanimous Recommendation by Independent Data Monitoring Committee to Continue and Complete Phase III HEAT Study of ThermoDox in Primary Liver Cancer as Planned Company May Conduct Additional Interim Eff
Celsion Announces Unanimous Recommendation by Independent Data Monitoring Committee to Continue and Complete Phase III HEAT Study of ThermoDox in Primary Liver Cancer as Planned Company May Conduct Additional Interim Efficacy Analyses Following Agreement Reconfirms 380 PFS Ev
Read more →IMNNCelsion Reports Third Quarter 2011 Financial Results and Provides Business Updates Company to Hold Conference Call Thursday, November 10 th at 11:00 a.m.
Celsion Reports Third Quarter 2011 Financial Results and Provides Business Updates Company to Hold Conference Call Thursday, November 10th at 11:00 a.m. ET LAWRENCEVILLE, NJ - November 10, 2011 - Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development company, to
Read more →IMNNCelsion Reports Second Quarter 2011 Financial Results and Provides Business Updates Company to Hold Conference Call Tuesday, August 9 th at 11:00 a.m.
Celsion Reports Second Quarter 2011 Financial Results and Provides Business Updates Company to Hold Conference Call Tuesday, August 9th at 11:00 a.m. ET COLUMBIA, MD - August 9, 2011 - Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development company, today announc
Read more →IMNNCelsion Announces Closing of $18.4 Million in Financing Triggers Conversion of All Preferred Stock COLUMBIA, MD
Celsion Announces Closing of $18.4 Million in Financing Triggers Conversion of All Preferred Stock COLUMBIA, MD July 25, 2011 Celsion Corporation (the Company ) (NASDAQ:CLSN) today announced the closings of its previously announced sales of an aggregate of $18.4 million of the
Read more →IMNN(h) Substantial Completion.
Suite No.: 100, 997 Lenox Drive, Lawrenceville, NJ THIS LEASE ("Lease") is entered into as of the 21 day of July, 2011, between BRANDYWINE OPERATING PARTNERSHIP, L.P., a Delaware limited partnership ("Landlord"), and CELSION CORPORATION, a Delaware corporation with its principal
Read more →IMNNCelsion Corporation Announces Closing of $6.6 Million Registered Direct Offering COLUMBIA, MD
Celsion Corporation Announces Closing of $6.6 Million Registered Direct Offering COLUMBIA, MD - July 6, 2011 - Celsion Corporation (the "Company") (NASDAQ: CLSN) today announced the closing of its previously announced sale of $6.6 million of the Company's securities in a registe
Read more →IMNNCelsion Corporation Announces $6.6 Million Registered Direct Offering COLUMBIA, MD
Celsion Corporation Announces $6.6 Million Registered Direct Offering COLUMBIA, MD - July 1, 2011 - Celsion Corporation (the "Company") (NASDAQ:CLSN) today announced that it has received commitments from institutional investors to purchase an aggregate of $6.6 million of the Com
Read more →IMNNCelsion Corporation Announces $8.6 Million Equity Offering of Common Stock and Warrants COLUMBIA, MD
Celsion Corporation Announces $8.6 Million Equity Offering of Common Stock and Warrants COLUMBIA, MD - May 27, 2011 - Celsion Corporation (the "Company") (NASDAQ:CLSN), a leading oncology drug development company, today announced that it has entered into a definitive securities
Read more →IMNNCELSION CORPORATION REPORTS YEAR END 2010 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Company to Hold Conference Call Today at 11:00 a.m. ET Columbia, MD - (MARKET WIRE)
CELSION CORPORATION REPORTS YEAR END 2010 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Company to Hold Conference Call Today at 11:00 a.m. ET Columbia, MD - (MARKET WIRE) - March 25, 2011 - Celsion Corporation (NASDAQ:CLSN), a leading oncology drug development company, today
Read more →Competitive Position
How IMNN ranks across every disease it competes inCompetitive Position is a premium feature
See how IMNN ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial